JP2022172150A - 制御可能な薬物送達システム及び使用方法 - Google Patents
制御可能な薬物送達システム及び使用方法 Download PDFInfo
- Publication number
- JP2022172150A JP2022172150A JP2022129187A JP2022129187A JP2022172150A JP 2022172150 A JP2022172150 A JP 2022172150A JP 2022129187 A JP2022129187 A JP 2022129187A JP 2022129187 A JP2022129187 A JP 2022129187A JP 2022172150 A JP2022172150 A JP 2022172150A
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- patient
- drug
- reservoir
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 529
- 238000000034 method Methods 0.000 title claims description 227
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 135
- 238000004891 communication Methods 0.000 claims abstract description 101
- 239000012530 fluid Substances 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims description 174
- 229940079593 drug Drugs 0.000 claims description 149
- 230000004888 barrier function Effects 0.000 claims description 136
- 230000036512 infertility Effects 0.000 claims description 68
- 238000010438 heat treatment Methods 0.000 claims description 52
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 230000015654 memory Effects 0.000 claims description 21
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 238000004659 sterilization and disinfection Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 10
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims description 7
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims description 7
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims description 7
- 230000001681 protective effect Effects 0.000 claims description 7
- 239000003173 antianemic agent Substances 0.000 claims description 6
- 102000005741 Metalloproteases Human genes 0.000 claims description 5
- 108010006035 Metalloproteases Proteins 0.000 claims description 5
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 5
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 5
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 claims description 4
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 2
- 108091008803 APLNR Proteins 0.000 claims 3
- 102000016555 Apelin receptors Human genes 0.000 claims 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 3
- 239000000018 receptor agonist Substances 0.000 claims 3
- 229940044601 receptor agonist Drugs 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 49
- 239000000825 pharmaceutical preparation Substances 0.000 description 43
- 229940126534 drug product Drugs 0.000 description 40
- 229940090047 auto-injector Drugs 0.000 description 38
- 238000002347 injection Methods 0.000 description 36
- 239000007924 injection Substances 0.000 description 36
- 230000008859 change Effects 0.000 description 25
- 238000010586 diagram Methods 0.000 description 18
- 238000003780 insertion Methods 0.000 description 15
- 230000037431 insertion Effects 0.000 description 15
- 230000009471 action Effects 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000000712 assembly Effects 0.000 description 12
- 238000000429 assembly Methods 0.000 description 12
- 238000001816 cooling Methods 0.000 description 11
- 230000007613 environmental effect Effects 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 11
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000012795 verification Methods 0.000 description 9
- 108010074604 Epoetin Alfa Proteins 0.000 description 8
- 102100034980 ICOS ligand Human genes 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000000994 depressogenic effect Effects 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 6
- 102100036509 Erythropoietin receptor Human genes 0.000 description 6
- 108010029961 Filgrastim Proteins 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229960001972 panitumumab Drugs 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 230000001010 compromised effect Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 108010002601 epoetin beta Proteins 0.000 description 5
- 229960004579 epoetin beta Drugs 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108010044644 pegfilgrastim Proteins 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000011179 visual inspection Methods 0.000 description 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 4
- 101710093458 ICOS ligand Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000000881 depressing effect Effects 0.000 description 4
- 108010067416 epoetin delta Proteins 0.000 description 4
- 229950002109 epoetin delta Drugs 0.000 description 4
- 108010081679 epoetin theta Proteins 0.000 description 4
- 229950008826 epoetin theta Drugs 0.000 description 4
- 108010030868 epoetin zeta Proteins 0.000 description 4
- 229950005185 epoetin zeta Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 102000044389 human CD22 Human genes 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 3
- 102100034608 Angiopoietin-2 Human genes 0.000 description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 108010019673 Darbepoetin alfa Proteins 0.000 description 3
- 108010008165 Etanercept Proteins 0.000 description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 3
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 3
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 3
- -1 darbepoietin Chemical compound 0.000 description 3
- 229960001251 denosumab Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960003388 epoetin alfa Drugs 0.000 description 3
- 229960004177 filgrastim Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940071846 neulasta Drugs 0.000 description 3
- 229940029345 neupogen Drugs 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229940071643 prefilled syringe Drugs 0.000 description 3
- 230000001012 protector Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 108010017584 romiplostim Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 2
- 101710148535 Thrombopoietin receptor Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940115115 aranesp Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229950007296 cantuzumab mertansine Drugs 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940089118 epogen Drugs 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010013846 hematide Proteins 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 108010010648 interferon alfacon-1 Proteins 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- 229960000994 lumiracoxib Drugs 0.000 description 2
- 229940029238 mircera Drugs 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
- 229960001373 pegfilgrastim Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000012782 phase change material Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UHTZABZWCSJMDY-UHFFFAOYSA-N 2-(chloromethyl)oxirane;n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound ClCC1CO1.NCCCN(CCCN)CCCCN(CCCN)CCCN UHTZABZWCSJMDY-UHFFFAOYSA-N 0.000 description 1
- PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 1
- HPNRHPKXQZSDFX-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound N1C(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2N(CCC2)C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2N=CNC=2)C(O)=O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C1CC1=CC=CC=C1 HPNRHPKXQZSDFX-UHFFFAOYSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 229960005509 CAT-3888 Drugs 0.000 description 1
- 229960005517 CAT-5001 Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100179591 Caenorhabditis elegans ins-22 gene Proteins 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- CZNVSLGYWMSMKE-OPDGVEILSA-K Ferric gluconate Chemical compound [Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CZNVSLGYWMSMKE-OPDGVEILSA-K 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000687727 Homo sapiens Transcriptional regulator PINT87aa Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 230000005679 Peltier effect Effects 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102100024797 Transcriptional regulator PINT87aa Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000002691 anti-thymic effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229950007940 bixalomer Drugs 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 108700001003 carbamylated erythropoietin Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229940102709 ferumoxytol Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 229940063135 genotropin Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 102000053529 human TNFSF11 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229940065770 humatrope Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940032961 iron sucrose Drugs 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229940054205 natrecor Drugs 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 108010048732 pegylated erythropoietin Proteins 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 229940092597 prolia Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940116949 sensipar Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000013068 supply chain management Methods 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229950009578 vidupiprant Drugs 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229940014556 xgeva Drugs 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31501—Means for blocking or restricting the movement of the rod or piston
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31568—Means keeping track of the total dose administered, e.g. since the cartridge was inserted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
- A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Social work
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
- A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/60—General characteristics of the apparatus with identification means
- A61M2205/6009—General characteristics of the apparatus with identification means for matching patient with his treatment, e.g. to improve transfusion security
Abstract
【解決手段】薬物送達システムであって、貯蔵部712、前記貯蔵部712と流体連通している近位端716及び患者内に受容される遠位端718を有する送達カニューレ714、ならびに制御可能要素を備える、薬物送達装置700と、前記薬物送達装置700に結合されたセンサ760,762、764と、前記センサ及び前記制御可能要素に結合された制御装置750であって、前記センサを使用して、前記薬物送達装置700の条件または動作状態を判定し、前記薬物送達装置700の前記条件または動作状態に基づいて、前記制御可能要素を制御するように構成される制御装置750と、を備える。
【選択図】図12
Description
2014年6月3日出願の米国特許仮出願第62/007,007号の優先権利益が主張され、その全内容は参照により本明細書に明示的に組み込まれる。
(i)次の特許公開の中に記載されている抗体1A(DSMZ受託番号DSM ACC 2586)、抗体8(DSMZ受託番号DSM ACC 2589)、抗体23(DSMZ受託番号DSM ACC 2588)、及び抗体18を含むがこれらに限定されない、米国特許公開第2006/0040358号(2006年2月23日公開)、同第2005/0008642号(2005年1月13日公開)、同第2004/0228859号(2004年11月18日公開)、
(ii)次の中に記載される抗体2F8、A12、及びIMC-A12を含むがこれらに限定されない、PCT公開第WO06/138729号(2006年12月28日公開)及び同第WO05/016970号(2005年2月24日公開)、及びLu et al.(2004),J.Biol.Chem.279:2856-2865、
(iii)PCT公開第WO07/012614号(2007年2月1日公開)、同第WO07/000328号(2007年1月4日公開)、同第WO06/013472号(2006年2月9日公開)、同第WO05/058967号(2005年6月30日公開)、及び同第WO03/059951号(2003年7月24日公開)、
(iv)次の特許公開の中に記載される抗体7C10、キメラ抗体C7C10、抗体h7C10、抗体7H2M、キメラ抗体*7C10、抗体GM607、ヒト化抗体7C10バージョン1、ヒト化抗体7C10バージョン2、ヒト化抗体7C10バージョン3、及び抗体7H2HMを含むがこれらに限定されない、米国特許公開第2005/0084906号(2005年4月21日公開)、
(v)次のものの中に記載される抗体EM164、再表面形成されたEM164、ヒト化EM164、huEM164 v1.0、huEM164 v1.1、huEM164 v1.2、及びhuEM164 v1.3を含むがこれらに限定されない、米国特許公開第2005/0249728号(2005年11月10日公開)、同第2005/0186203号(2005年8月25日公開)、同第2004/0265307号(2004年12月30日公開)、及び同第2003/0235582号(2003年12月25日公開)、ならびにMaloney et al.(2003),Cancer Res.63:5073-5083、
(vi)次の中に記載されるATCC受託番号PTA-2792、PTA-2788、PTA-2790、PTA-2791、PTA-2789、PTA-2793、及び抗体2.12.1、2.13.2、2.14.3、3.1.1、4.9.2、及び4.17.3を有するハイブリドーマによって産生された抗体の各々を含むがこれらに限定されない、抗体CP-751,871などの、米国特許第7,037,498号(2006年5月2日発行)、米国特許公開第2005/0244408号(2005年11月30日公開)及び同第2004/0086503号(2004年5月6日公開)、及びCohen,et al.(2005),Clinical Cancer Res.11:2063-2073、
(vii)次の特許公開の中に記載される抗体19D12と、ATCCに受託番号PTA-5214で受託されているプラスミド15H12/19D12 HCA(γ4)のポリヌクレオチドによってコードされる重鎖、及びATCCに受託番号PTA-5220で受託されているプラスミド15H12/19D12 LCF(κ)のポリヌクレオチドによってコードされる軽鎖を含む抗体と、を含むがこれらに限定されない、米国特許公開第2005/0136063号(2005年6月23日公開)及び同第2004/0018191号(2004年1月29日公開)、ならびに
(viii)各々及び全てが、特にIGF-1受容体を標的にする前述の抗体、ペプチボディ、及び関連タンパク質等に関して参照によりその全体が本明細書に組み込まれる次の特許公開の中に記載される抗体PINT-6A1、PINT-7A2、PINT-7A4、PINT-7A5、PINT-7A6、PINT-8A1、PINT-9A2、PINT-11A1、PINT-11A2、PINT-11A3、PINT-11A4、PINT-11A5、PINT-11A7、PINT-11A12、PINT-12A1、PINT-12A2、PINT-12A3、PINT-12A4、及びPINT-12A5を含むがこれらに限定されない、米国特許公開第2004/0202655号(2004年10月14日公開)、
Claims (79)
- 薬物送達システムであって、
貯蔵部、前記貯蔵部と流体連通している近位端及び患者内に受容される遠位端を有する送達カニューレ、ならびに制御可能要素を備える、薬物送達装置と、
前記薬物送達装置に結合されたセンサと、
前記センサ及び前記制御可能要素に結合された制御装置であって、
前記センサを使用して、前記薬物送達装置の条件または動作状態を判定し、
前記薬物送達装置の前記条件または動作状態に基づいて、前記制御可能要素を制御するように構成される制御装置とを備える、薬物送達システム。 - 前記制御可能要素は、ロックを含む、請求項1に記載の薬物送達システム。
- 前記薬物送達装置は、前記送達カニューレの前記遠位端に対して可動である針シールドを備え、
前記ロックは、前記ロックが作動すると前記針シールドの動きを防ぐように構成される、請求項2に記載の薬物送達システム。 - 前記薬物送達装置は、前記貯蔵部から薬剤を放出するための、前記貯蔵部を通って可動であるプランジャーを備え、
前記ロックは、前記ロックが作動すると前記プランジャーの動きを防ぐように構成される、請求項2に記載の薬物送達システム。 - 前記薬物送達装置は、前記薬物送達装置を始動させるように構成されたアクチュエータを備え、
前記ロックは、前記ロックが作動すると前記アクチュエータが前記薬物送達装置を始動させることを防ぐように構成される、請求項2に記載の薬物送達システム。 - 前記薬物送達装置は、前記送達カニューレの前記遠位端の周囲に配設された着脱可能な滅菌バリアを備え、
前記センサは、前記着脱可能な滅菌バリアの動きを検出するように構成され、
前記制御装置は、
前記センサを使用して、前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去されたかどうかを判定し、
前記着脱可能な滅菌バリアの除去から一定期間が経過したかどうかを判定し、
前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去され、かつ前記一定期間が経過した場合、前記ロックを作動させるように構成される、請求項2~5のいずれか一項に記載の薬物送達システム。 - 前記センサは、前記貯蔵部内の薬剤の温度を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記貯蔵部内の前記薬剤の前記温度または温度履歴を判定し、
前記貯蔵部内の前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記ロックを作動させるように構成される、請求項2~5のいずれか一項に記載の薬物送達システム。 - 前記センサは、前記患者の識別を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記患者が権限を与えられた患者であるかどうかを判定し、
前記患者が前記権限を与えられた患者である場合、前記ロックを解除するように構成される、請求項2~5のいずれか一項に記載の薬物送達システム。 - 前記センサは、指紋センサを含む、請求項8に記載の薬物送達システム。
- 前記薬物送達装置は、前記送達カニューレの前記遠位端のための開口部を有するハウジングを備え、
前記センサは、前記ハウジングと対象物との間の接触を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記ハウジングが前記患者に接触しているかどうかを判定し、
前記ハウジングが前記患者に接触している場合、前記ロックを解除するように構成される、請求項2~5のいずれか一項に記載の薬物送達システム。 - 前記センサは、前記送達カニューレの配向を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記送達カニューレが前記貯蔵部内の薬剤を前記患者に送達するために配向されているかどうかを判定し、
前記送達カニューレが前記貯蔵部内の前記薬剤を前記患者に送達するために配向されている場合、前記ロックを解除するように構成される、請求項2~5のいずれか一項に記載の薬物送達システム。 - 前記制御装置は、
前記貯蔵部内の薬剤の有効期限を保存し、
現在の日付が前記貯蔵部内の前記薬剤の前記有効期限以降である場合、前記ロックを作動させるように構成される、請求項2~5のいずれか一項に記載の薬物送達システム。 - 前記制御可能要素は、低エネルギー状態及び高エネルギー状態を有する回路を含む、請求項1に記載の薬物送達システム。
- 前記薬物送達装置は、前記送達カニューレの前記遠位端の周囲に配設された着脱可能な滅菌バリアを備え、
前記センサは、前記着脱可能な滅菌バリアの動きを検出するように構成され、
前記制御装置は、
前記センサを使用して、前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去されたかどうかを判定し、
前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去された場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えるように構成される、請求項13に記載の薬物送達システム。 - 前記センサは、前記貯蔵部内の薬剤の温度を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記貯蔵部内の前記薬剤の前記温度または温度履歴を判定し、
前記貯蔵部内の前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えるように構成される、請求項13に記載の薬物送達システム。 - 前記薬物送達装置は、前記送達カニューレの前記遠位端のための開口部を有するハウジングを備え、
前記センサは、前記ハウジングと対象物との間の接触を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記ハウジングが前記患者に接触しているかどうかを判定し、
前記ハウジングが前記患者に接触している場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えるように構成される、請求項13に記載の薬物送達システム。 - 前記センサは、前記薬物送達装置の外部周囲に配設された保護包装に対する前記薬物送達装置の動きを検出するように構成され、
前記制御装置は、
前記センサを使用して、前記薬物送達装置が前記保護包装から取り出されたかどうかを判定し、
薬物送達装置が前記保護包装から取り出されている場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えるように構成される、請求項13に記載の薬物送達システム。 - 前記制御可能要素は、作動すると前記貯蔵部または前記送達カニューレ内の薬剤を加熱するように構成された加熱要素を含む、請求項1に記載の薬物送達システム。
- 前記薬物送達装置は、前記送達カニューレの前記遠位端の周囲に配設された着脱可能な滅菌バリアを備え、
前記センサは、前記着脱可能な滅菌バリアの動きを検出するように構成され、
前記制御装置は、
前記センサを使用して、前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去されたかどうかを判定し、
前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去された場合、前記加熱要素を作動させるように構成される、請求項18に記載の薬物送達システム。 - 前記センサは、前記貯蔵部内の薬剤の温度を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記貯蔵部内の前記薬剤の前記温度または温度履歴を判定し、
前記貯蔵部内の前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記加熱要素を作動させるように構成される、請求項18に記載の薬物送達システム。 - 前記薬物送達装置は、前記送達カニューレの前記遠位端のための開口部を有するハウジングを備え、
前記センサは、前記ハウジングと対象物との間の接触を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記ハウジングが前記患者に接触しているかどうかを判定し、
前記ハウジングが前記患者に接触している場合、前記加熱要素を作動させるように構成される、請求項18に記載の薬物送達システム。 - 前記薬物送達装置は、前記薬物送達装置を始動させるように構成されたアクチュエータを備え、
前記センサは、前記アクチュエータの動きを検出するように構成され、
前記制御装置は、
前記センサを使用して、前記アクチュエータが前記薬物送達装置を始動させるために使用されたかどうかを判定し、
前記アクチュエータが前記薬物送達装置を始動させるために使用された場合、前記加熱要素を作動させるように構成される、請求項18に記載の薬物送達システム。 - 前記加熱要素は、前記貯蔵部または前記送達カニューレに結合された導電性コイルを含む、請求項18~22のいずれか一項に記載の薬物送達システム。
- 前記制御可能要素は、出力ユニットを含む、請求項1に記載の薬物送達システム。
- 前記センサは、前記貯蔵部内の薬剤の温度を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記貯蔵部内の前記薬剤の前記温度または温度履歴を判定し、
前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記薬物送達装置が前記薬剤を前記患者に送達するために使用されるべきではないことを前記患者に通知するために、前記出力ユニットを制御するように構成される、請求項24に記載の薬物送達システム。 - 前記センサは、前記送達カニューレの配向を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記送達カニューレが前記貯蔵部内の薬剤を前記患者に送達するために配向されているかどうかを判定し、
前記送達カニューレが前記薬剤を前記患者に送達するために配向されている場合、前記薬物送達装置が前記薬剤を前記患者に送達するために使用され得ることを前記患者に通知するために、前記出力ユニットを制御するように構成される、請求項24に記載の薬物送達システム。 - 前記薬物送達装置は、前記送達カニューレの前記遠位端のための開口部を有するハウジングを備え、
前記センサは、前記ハウジングと対象物との間の接触を検出するように構成され、
前記制御装置は、
前記センサを使用して、前記ハウジングが前記患者に接触しているかどうかを判定し、
前記ハウジングが前記患者に接触している場合、前記薬物送達装置が前記貯蔵部内の薬剤を前記患者に送達するために使用され得ることを前記患者に通知するために、前記出力ユニットを制御するように構成される、請求項24に記載の薬物送達システム。 - 前記薬物送達装置は、前記貯蔵部から薬剤を放出するための、前記貯蔵部を通って可動であるプランジャーを備え、
前記センサは、前記プランジャーの動きを検出するように構成され、
前記制御装置は、
前記センサを使用して、前記プランジャーが送達行程を完了したかどうかを判定し、
前記プランジャーが前記送達工程を完了した場合、前記貯蔵部から前記患者への前記薬剤の送達の完了を前記患者に通知するために、前記出力ユニットを制御するように構成される、請求項24に記載の薬物送達システム。 - 前記出力ユニットは、表示装置、タッチスクリーン、発光ダイオード、振動器、スピーカー、または警報器のうちの少なくとも1つを含む、請求項24~28のいずれか一項に記載の薬物送達システム。
- 前記薬物送達装置は、
前記貯蔵部及び前記送達カニューレを格納するハウジングと、
前記ハウジングの遠位端の周囲に配設された、少なくとも1つの回転抑制外部側面を有する、着脱可能な滅菌バリアとを備える、請求項1~29のいずれか一項に記載の薬物送達システム。 - 前記着脱可能な滅菌バリアは、三角形の断面を有する、請求項30に記載の薬物送達システム。
- 前記着脱可能な滅菌バリアは、平坦な遠位端表面を有し、前記少なくとも1つの回転抑制外部側面は、前記平坦な遠位端表面に対して垂直である、請求項30または31に記載の薬物送達システム。
- 前記着脱可能な滅菌バリアは、被覆部材及び管状部材を含み、前記被覆部材は、前記管状部材の開口端を被覆し、前記管状部材は、前記着脱可能な滅菌バリアを前記ハウジングから除去するときに前記患者によって掴持される複数の外向きに突き出たリブを含む、請求項30~33のいずれか一項に記載の薬物送達システム。
- 前記制御装置または前記センサのうちの少なくとも1つは、前記着脱可能な滅菌バリア内に収容される、請求項30~33のいずれか一項に記載の薬物送達ステム。
- 前記貯蔵部は、薬剤を含む、請求項1~34のいずれか一項に記載の薬物送達システム。
- 前記薬剤は、TNF阻害剤、カルシトニン遺伝子関連ペプチド受容体に対する抗体、顆粒球コロニー刺激因子、赤血球生成促進剤、アペリン受容体作動薬、プロタンパク質転換酵素サブチリシン/ケキシン9型(PCSK9)に対する抗体、及びメタロプロテイナーゼの組織阻害剤からなる群から選択される、請求項35に記載の薬物送達システム。
- 薬物送達システムであって、
貯蔵部、前記貯蔵部と流体連通している近位端及び患者内に受容される遠位端を有する送達カニューレ、ならびに制御可能要素を備える、薬物送達装置と、
前記患者の識別、前記薬物送達装置の識別、または前記貯蔵部内に保持される薬剤の識別のうちの少なくとも1つを表す識別情報を保存するように構成されたメモリと、
前記メモリ及び前記制御可能要素に結合された制御装置であって、前記識別情報に基づいて前記制御可能要素を制御するように構成される制御装置とを備える、薬物送達システム。 - 前記制御可能要素は、ロックを含む、請求項37に記載の薬物送達システム。
- 前記薬物送達装置は、前記送達カニューレの前記遠位端に対して可動である針シールドを備え、
前記ロックは、前記ロックが作動すると前記針シールドの動きを防ぐように構成される、請求項38に記載の薬物送達システム。 - 前記薬物送達装置は、前記貯蔵部から薬剤を放出するための、前記貯蔵部を通って可動であるプランジャーを備え、
前記ロックは、前記ロックが作動すると前記プランジャーの動きを防ぐように構成される、請求項38に記載の薬物送達システム。 - 前記薬物送達装置は、前記薬物送達装置を始動させるように構成されたアクチュエータを備え、
前記ロックは、前記ロックが作動すると前記薬物送達装置を始動させることから前記アクチュエータに構成される、請求項38に記載の薬物送達システム。 - 前記識別情報は、前記貯蔵部内に保持される前記薬剤の有効期限を示し、
前記制御装置は、現在の日付が前記貯蔵部内の前記薬剤の前記有効期限以降である場合、前記ロックを作動させるように構成される、請求項38~41のいずれか一項に記載の薬物送達システム。 - 前記薬物送達装置は、入力ユニットを備え、
前記識別情報は、パスワードを含み、
前記制御装置は、前記入力ユニットを介して入力されたパスワードが、前記識別情報に含まれている前記パスワードと一致する場合、前記ロックを解除するように構成される、請求項38~41のいずれか一項に記載の薬物送達システム。 - 前記制御可能要素は、表示装置を含み、
前記制御装置は、前記識別情報を表示させるために前記表示装置を制御するように構成される、請求項37に記載の薬物送達システム。 - 前記識別情報は、前記貯蔵部内に保持される前記薬剤の有効期限を含む、請求項44に記載の薬物送達システム。
- 前記識別情報は、薬物名、薬物濃度、投与量情報、前記薬物送達装置の通し番号、前記貯蔵部内に保持される前記薬剤の通し番号、薬物送達装置の種類、前記貯蔵部内に保持される前記薬剤の種類、前記薬物送達装置の製造日、権限を与えられた患者の名前、パスワード、生体情報、人口統計データ情報、または患者サブグループ情報のうちの少なくとも1つを含む、請求項37~45のいずれか一項に記載の薬物送達システム。
- 前記薬物送達装置は、
前記貯蔵部及び前記送達カニューレを格納するハウジングと、
前記ハウジングの遠位端の周囲に配設された、少なくとも1つの回転抑制外部側面を有する着脱可能な滅菌バリアとを備える、請求項37~46のいずれか一項に記載の薬物送達システム。 - 前記着脱可能な滅菌バリアは、三角形の断面を有する、請求項47に記載の薬物送達システム。
- 前記着脱可能な滅菌バリアは、平坦な遠位端表面を有し、前記少なくとも1つの回転抑制外部側面は、前記平坦な遠位端表面に対して垂直である、請求項47または48に記載の薬物送達システム。
- 前記着脱可能な滅菌バリアは、被覆部材及び管状部材を含み、前記被覆部材は、前記管状部材の開口端を被覆し、前記管状部材は、前記着脱可能な滅菌バリアを前記ハウジングから除去するときに前記患者によって掴持される複数の外向きに突き出たリブを含む、請求項47~49のいずれか一項に記載の薬物送達システム。
- 前記制御装置または前記メモリのうちの少なくとも1つは、前記着脱可能な滅菌バリア内に収容される、請求項47~50のいずれか一項に記載の薬物送達ステム。
- 前記貯蔵部は、前記薬剤を含む、請求項37~51のいずれか一項に記載の薬物送達システム。
- 前記薬剤は、TNF阻害剤、カルシトニン遺伝子関連ペプチド受容体に対する抗体、顆粒球コロニー刺激因子、赤血球生成促進剤、アペリン受容体作動薬、プロタンパク質転換酵素サブチリシン/ケキシン9型(PCSK9)に対する抗体、及びメタロプロテイナーゼの組織阻害剤からなる群から選択される、請求項52に記載の薬物送達システム。
- 貯蔵部、前記貯蔵部と流体連通している近位端及び患者内に受容される遠位端を有する送達カニューレ、前記送達カニューレの前記第2の端の周囲に配設された着脱可能な滅菌バリア、ならびに制御可能要素を備える、薬物送達装置と一緒に使用するための方法であって、
1つ以上のセンサを用いて、前記薬物送達装置の条件または動作状態を判定することと、
前記薬物送達装置の前記条件または動作状態に基づいて、前記制御可能要素を制御することと、を含む、方法。 - 前記制御可能要素は、ロックを含む、請求項54に記載の方法。
- 前記1つ以上のセンサを用いて、着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去されたかどうかを判定することと、
前記着脱可能な滅菌バリアの除去から一定期間が経過したかどうかを判定することと、
前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去され、かつ前記一定期間が経過した場合、前記ロックを作動させることと、を含む、請求項55に記載の方法。 - 前記1つ以上のセンサを用いて、前記貯蔵部内の薬剤の温度を判定することと、
前記貯蔵部内の前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記ロックを作動させることと、を含む、請求項55または56に記載の方法。 - 前記1つ以上のセンサを用いて、前記患者が権限を与えられた患者であるかどうかを判定することと、
前記患者が前記権限を与えられた患者である場合、前記ロックを解除することと、を含む、請求項55~57のいずれか一項に記載の方法。 - 前記1つ以上のセンサを用いて、前記薬物送達装置のハウジング接点が前記患者に接触しているかどうかを判定することと、
前記ハウジングが前記患者に接触している場合、前記ロックを解除することと、を含む、請求項55~58のいずれか一項に記載の方法。 - 前記1つ以上のセンサを用いて、前記送達カニューレが前記貯蔵部内の薬剤を前記患者に送達するために配向されているかどうかを判定することと、
前記送達カニューレが前記貯蔵部内の前記薬剤を前記患者に送達するために配向されている場合、前記ロックを解除することと、を含む、請求項55~59のいずれか一項に記載の方法。 - 前記薬物送達装置に搭載されたメモリ内に有効期限を保存することと、
現在の日付が前記貯蔵部内の前記薬剤の前記有効期限以降である場合、前記ロックを作動させることと、を含む、請求項55~60のいずれか一項に記載の方法。 - 前記制御可能要素は、低エネルギー状態及び高エネルギー状態を有する回路を含む、請求項54に記載の方法。
- 前記1つ以上のセンサを用いて、着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去されたかどうかを判定することと、
前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去された場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えることと、を含む、請求項62のいずれか一項に記載の方法。 - 前記1つ以上のセンサを用いて、前記貯蔵部内の薬剤の温度または温度履歴を判定することと、
前記貯蔵部内の前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えることと、を含む、請求項62または63に記載の方法。 - 前記1つ以上のセンサを用いて、前記薬物送達装置のハウジングが前記患者に接触しているかどうかを判定することと、
前記ハウジングが前記患者に接触している場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えることと、を含む、請求項62~64のいずれか一項に記載の方法。 - 前記1つ以上のセンサを用いて、前記薬物送達装置が保護包装から取り出されたかどうかを判定することと、
薬物送達装置が前記保護包装から取り出された場合、前記回路を前記低エネルギー状態から前記高エネルギー状態に切り替えることと、を含む、請求項62~65のいずれか一項に記載の方法。 - 前記制御可能要素は、作動すると前記貯蔵部または前記送達カニューレ内の薬剤を加熱するように構成された加熱要素を含む、請求項54に記載の方法。
- 前記1つ以上のセンサを用いて、着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去されたかどうかを判定することと、
前記着脱可能な滅菌バリアが前記送達カニューレの前記遠位端から除去された場合、前記加熱要素を作動させることと、を含む、請求項67のいずれか一項に記載の方法。 - 前記1つ以上のセンサを用いて、前記貯蔵部内の薬剤の温度または温度履歴を判定することと、
前記貯蔵部内の前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記加熱要素を作動させることと、を含む、請求項67または68に記載の方法。 - 前記1つ以上のセンサを用いて、前記薬物送達装置のハウジングが前記患者に接触しているかどうかを判定することと、
前記ハウジングが前記患者に接触している場合、前記加熱要素を作動させることと、を含む、請求項67~69のいずれか一項に記載の方法。 - 前記1つ以上のセンサを用いて、アクチュエータが前記薬物送達装置を始動させるために使用されたかどうかを判定することと、
前記アクチュエータが前記薬物送達装置を始動させるために使用された場合、前記加熱要素を作動させることと、を含む、請求項67~70のいずれか一項に記載の方法。 - 前記制御可能要素は、出力ユニットを含む、請求項54に記載の方法。
- 前記1つ以上のセンサを用いて、前記貯蔵部内の薬剤の温度または温度履歴を判定することと、
前記薬剤の前記温度または温度履歴が標的温度より高いか、またはそれ未満である場合、前記出力ユニットを用いて、前記薬物送達装置が前記薬剤を前記患者に送達するために使用されるべきではないことを前記患者に通知することと、を含む、請求項72に記載の方法。 - 前記1つ以上のセンサを用いて、送達カニューレが前記貯蔵部内の薬剤を前記患者に送達するために配向されているかどうかを判定することと、
前記送達カニューレが前記薬剤を前記患者に送達するために配向されている場合、前記出力ユニットを用いて、前記薬物送達装置が前記薬剤を前記患者に送達するために使用され得ることを前記患者に通知することと、を含む、請求項72または73に記載の方法。 - 前記1つ以上のセンサを用いて、前記薬物送達装置のハウジングが前記患者に接触しているかどうかを判定することと、
前記ハウジングが前記患者に接触している場合、前記出力ユニットを用いて、前記薬物送達装置が前記貯蔵部内の薬剤を前記患者に送達するために使用され得ることを前記患者に通知することと、を含む、請求項72~74のいずれか一項に記載の方法。 - 前記1つ以上のセンサを用いて、プランジャーが送達工程を完了したかどうかを判定することと、
前記プランジャーが前記送達工程を完了した場合、前記出力ユニットを用いて、前記貯蔵部から前記患者への前記薬剤の送達の完了を前記患者に通知することと、を含む、請求項72~75のいずれか一項に記載の方法。 - 前記出力ユニットは、表示装置、タッチスクリーン、発光ダイオード、振動器、スピーカー、または警報器のうちの少なくとも1つを含む、請求項72~76のいずれか一項に記載の方法。
- 前記貯蔵部は、薬剤を含む、請求項54~77のいずれか一項に記載の方法。
- 前記薬剤は、TNF阻害剤、カルシトニン遺伝子関連ペプチド受容体に対する抗体、顆粒球コロニー刺激因子、赤血球生成促進剤、アペリン受容体作動薬、プロタンパク質転換酵素サブチリシン/ケキシン9型(PCSK9)に対する抗体、及びメタロプロテイナーゼの組織阻害剤からなる群から選択される、請求項78に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462007007P | 2014-06-03 | 2014-06-03 | |
US62/007,007 | 2014-06-03 | ||
JP2020213220A JP7126540B2 (ja) | 2014-06-03 | 2020-12-23 | 制御可能な薬物送達システム及び使用方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020213220A Division JP7126540B2 (ja) | 2014-06-03 | 2020-12-23 | 制御可能な薬物送達システム及び使用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022172150A true JP2022172150A (ja) | 2022-11-15 |
Family
ID=53385997
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016570991A Active JP6817074B2 (ja) | 2014-06-03 | 2015-06-03 | 制御可能な薬物送達システム及び使用方法 |
JP2016570990A Active JP6808494B2 (ja) | 2014-06-03 | 2015-06-03 | 薬物送達システム及び使用方法 |
JP2016571023A Active JP6822843B2 (ja) | 2014-06-03 | 2015-06-03 | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
JP2016571049A Active JP6742248B2 (ja) | 2014-06-03 | 2015-06-03 | 薬物送達装置の使用者を支援するための装置及び方法 |
JP2020178668A Pending JP2021035515A (ja) | 2014-06-03 | 2020-10-26 | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
JP2020203182A Active JP7100106B2 (ja) | 2014-06-03 | 2020-12-08 | 薬物送達システム及び使用方法 |
JP2020213220A Active JP7126540B2 (ja) | 2014-06-03 | 2020-12-23 | 制御可能な薬物送達システム及び使用方法 |
JP2022104384A Pending JP2022137121A (ja) | 2014-06-03 | 2022-06-29 | 薬物送達システム及び使用方法 |
JP2022129187A Pending JP2022172150A (ja) | 2014-06-03 | 2022-08-15 | 制御可能な薬物送達システム及び使用方法 |
JP2023218940A Pending JP2024050546A (ja) | 2014-06-03 | 2023-12-26 | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016570991A Active JP6817074B2 (ja) | 2014-06-03 | 2015-06-03 | 制御可能な薬物送達システム及び使用方法 |
JP2016570990A Active JP6808494B2 (ja) | 2014-06-03 | 2015-06-03 | 薬物送達システム及び使用方法 |
JP2016571023A Active JP6822843B2 (ja) | 2014-06-03 | 2015-06-03 | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
JP2016571049A Active JP6742248B2 (ja) | 2014-06-03 | 2015-06-03 | 薬物送達装置の使用者を支援するための装置及び方法 |
JP2020178668A Pending JP2021035515A (ja) | 2014-06-03 | 2020-10-26 | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
JP2020203182A Active JP7100106B2 (ja) | 2014-06-03 | 2020-12-08 | 薬物送達システム及び使用方法 |
JP2020213220A Active JP7126540B2 (ja) | 2014-06-03 | 2020-12-23 | 制御可能な薬物送達システム及び使用方法 |
JP2022104384A Pending JP2022137121A (ja) | 2014-06-03 | 2022-06-29 | 薬物送達システム及び使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023218940A Pending JP2024050546A (ja) | 2014-06-03 | 2023-12-26 | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
Country Status (11)
Country | Link |
---|---|
US (11) | US10695492B2 (ja) |
EP (5) | EP3151882B1 (ja) |
JP (10) | JP6817074B2 (ja) |
KR (6) | KR102506614B1 (ja) |
CN (7) | CN106470716B (ja) |
AU (13) | AU2015271767B2 (ja) |
CA (4) | CA2949846C (ja) |
IL (7) | IL281354B1 (ja) |
MX (8) | MX2016015853A (ja) |
SG (6) | SG11201609970VA (ja) |
WO (5) | WO2015187805A2 (ja) |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1762259T3 (da) | 2005-09-12 | 2011-01-03 | Unomedical As | Indføringsindretning til infusionssæt med en første og en anden fjederenhed |
CA2792138A1 (en) | 2010-03-30 | 2011-10-06 | Unomedical A/S | Medical device |
US10194938B2 (en) | 2011-03-14 | 2019-02-05 | UnoMedical, AS | Inserter system with transport protection |
US11197689B2 (en) | 2011-10-05 | 2021-12-14 | Unomedical A/S | Inserter for simultaneous insertion of multiple transcutaneous parts |
EP2583715A1 (en) | 2011-10-19 | 2013-04-24 | Unomedical A/S | Infusion tube system and method for manufacture |
US10441717B2 (en) | 2014-04-15 | 2019-10-15 | Insulet Corporation | Monitoring a physiological parameter associated with tissue of a host to confirm delivery of medication |
JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
US11478583B2 (en) | 2014-10-03 | 2022-10-25 | Enable Injections, Inc. | Medical fluid transfer and injection apparatus and method |
DK3265152T3 (da) | 2015-03-06 | 2020-03-23 | Attila Berey | Dataregistreringsorgan, særligt til en pen-lignende lægemiddelindgivesesindretning |
WO2016145206A1 (en) | 2015-03-10 | 2016-09-15 | Regeneron Pharmaceuticals, Inc. | Aseptic piercing system and method |
EP3103491A1 (en) * | 2015-06-10 | 2016-12-14 | Sanofi-Aventis Deutschland GmbH | A device for attachment to a drug delivery device |
WO2017062986A1 (en) * | 2015-10-09 | 2017-04-13 | Duke University | Medication administration and adherence systems and related methods |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
WO2017106247A1 (en) * | 2015-12-14 | 2017-06-22 | Amgen Inc. | Drug delivery storage device and system |
EP3184135A1 (en) * | 2015-12-22 | 2017-06-28 | Carebay Europe Ltd. | Communication device for transmitting information from a medicament delivery device |
RS63450B1 (sr) | 2015-12-30 | 2022-08-31 | Ascendis Pharma As | Auto-injektor sa sistemom za zadržavanje kertridža |
HUE060792T2 (hu) | 2015-12-30 | 2023-04-28 | Ascendis Pharma As | Önmûködõ fecskendõ |
CA3006638C (en) | 2015-12-30 | 2024-03-05 | Ascendis Pharma A/S | Auto injector with charger safety |
JP7335072B2 (ja) | 2015-12-30 | 2023-08-29 | アセンディス ファーマ エー/エス | 使用済みカートリッジの検出を備える自動注射器および関連の方法 |
EP3397318B1 (en) | 2015-12-30 | 2021-11-10 | Ascendis Pharma A/S | Auto injector with adaptable air-shot mechanism |
US11154661B2 (en) * | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
US11357912B2 (en) | 2016-01-19 | 2022-06-14 | Unomedical A/S | Cannula and infusion devices |
US20170237486A1 (en) * | 2016-02-11 | 2017-08-17 | West Pharmaceutical Services, Inc. | Visual communication between mobile communication devices and drug delivery devices |
JOP20170042B1 (ar) | 2016-02-12 | 2022-09-15 | Amgen Inc | وسيلة توصيل عقار، طريقة تصنيعه وطريقة استخدامه |
KR101957963B1 (ko) * | 2016-03-11 | 2019-07-04 | 이오플로우 주식회사 | 약액 주입 장치 |
EP3886113A1 (en) * | 2016-03-14 | 2021-09-29 | Fenwal, Inc. | Cell processing system and method with process parameter control |
US10747850B2 (en) * | 2016-03-29 | 2020-08-18 | International Business Machines Corporation | Medication scheduling and alerts |
WO2017177094A2 (en) * | 2016-04-08 | 2017-10-12 | Amgen Inc. | Drug delivery device, method of manufacture, and method of use |
US10953155B2 (en) | 2016-04-29 | 2021-03-23 | Verily Life Sciences Llc | Pressure sensor in plunger head to wake up electronics |
US10518039B2 (en) * | 2016-04-29 | 2019-12-31 | Verily Life Sciences Llc | Apparatus and methods for tracking administering of medication by medication injection devices |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11173247B2 (en) | 2016-07-14 | 2021-11-16 | Sanofi | Medicament delivery device |
EP3496782B1 (en) * | 2016-08-09 | 2021-09-15 | Roche Diabetes Care GmbH | Ambulatory infusion device |
JP6826392B2 (ja) * | 2016-08-10 | 2021-02-03 | 持田製薬株式会社 | 自動注射器 |
JP6415498B2 (ja) * | 2016-08-24 | 2018-10-31 | 株式会社スズケン | 医薬品在庫管理システム及び、医薬品在庫管理方法 |
KR20190053222A (ko) * | 2016-10-13 | 2019-05-17 | 에스에이치엘 메디컬 아게 | 약물 전달 장치를 위한 제어기 |
CN109792301A (zh) * | 2016-10-14 | 2019-05-21 | 艾斯曲尔医疗公司 | 配置为通过人体发送数据的自助给药装置 |
WO2018096534A1 (en) | 2016-11-22 | 2018-05-31 | Sorrel Medical Ltd. | Apparatus for delivering a therapeutic substance |
EP3326671A1 (en) * | 2016-11-29 | 2018-05-30 | Carebay Europe Ltd. | Activation assembly for a medicament delivery device |
US20190295707A1 (en) * | 2016-12-05 | 2019-09-26 | Quio Technologies Llc | Communication and tracking system for disposable drug delivery devices |
US20180165422A1 (en) * | 2016-12-08 | 2018-06-14 | Verily Life Sciences Llc | Systems and methods for controlling the operational state of a medical device |
MX2019006980A (es) * | 2016-12-28 | 2019-08-22 | Genentech Inc | Dispositivo de monitoreo de inyeccion. |
EP3345637B1 (en) * | 2017-01-09 | 2020-03-18 | Verily Life Sciences LLC | Systems and methods for wearable emergency drug injection devices |
CN106964014B (zh) * | 2017-02-13 | 2020-03-10 | 深圳麦科田生物医疗技术有限公司 | 一种输液管理方法及系统 |
CN114082048A (zh) | 2017-02-28 | 2022-02-25 | 伊莱利利公司 | 用于药物递送装置的剂量检测和药物识别 |
CA3058462A1 (en) | 2017-03-31 | 2018-10-04 | Becton, Dickinson And Company | Smart wearable injection and/or infusion device |
US20200276390A1 (en) * | 2017-04-19 | 2020-09-03 | Medimmune, Llc | E-connected auto-injectors |
US9993209B1 (en) * | 2017-04-24 | 2018-06-12 | International Business Machines Corporation | Dynamically monitoring environmental and physiological characteristics to generate a medicine ingestion alarm |
KR102540409B1 (ko) | 2017-05-05 | 2023-06-09 | 리제너론 파아마슈티컬스, 인크. | 자동 주사기 |
US10489287B2 (en) | 2017-05-15 | 2019-11-26 | Bank Of America Corporation | Conducting automated software testing using centralized controller and distributed test host servers |
US10845955B2 (en) | 2017-05-15 | 2020-11-24 | Apple Inc. | Displaying a scrollable list of affordances associated with physical activities |
US10223248B2 (en) | 2017-05-15 | 2019-03-05 | Bank Of America Corporation | Conducting automated software testing using centralized controller and distributed test host servers |
KR20230056801A (ko) | 2017-05-23 | 2023-04-27 | 아센디스 파마 에이에스 | 가변 플런저 힘을 갖는 자동 인젝터 |
EP3630231B1 (en) * | 2017-05-25 | 2023-11-01 | West Pharmaceutical Services, Inc. | Smart syringe using nfc communication and capacitance detection |
WO2018218082A1 (en) * | 2017-05-25 | 2018-11-29 | Enable Injections, Inc. | Medical fluid transfer and injection apparatus and method with compliance monitoring |
EP3630238B1 (en) * | 2017-05-30 | 2021-01-20 | West Pharma. Services Il, Ltd. | Vertical assembly of pcb |
WO2018222521A1 (en) | 2017-05-30 | 2018-12-06 | West Pharma. Services IL, Ltd. | Modular drive train for wearable injector |
US20200206025A1 (en) | 2017-06-13 | 2020-07-02 | Irenix Medical, Inc. | Active Agent Delivery Devices and Methods for Using the Same |
EP3641861A1 (en) * | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
US11957880B2 (en) | 2017-06-29 | 2024-04-16 | Ascendis Pharma A/S | Auto injector with reconstitution handling support |
IL308235A (en) | 2017-06-30 | 2024-01-01 | Regeneron Pharma | Automatic injection device with anti-rotation features and related methods |
DK3651830T3 (da) * | 2017-07-14 | 2023-11-20 | Sanofi Sa | Emballageindretning |
US11717615B2 (en) | 2017-07-14 | 2023-08-08 | Mannkind Corporation | Communication accessory for a drug delivery device |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
US11617837B2 (en) | 2017-07-25 | 2023-04-04 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
US20190053981A1 (en) * | 2017-08-17 | 2019-02-21 | Qualcomm Incorporated | Temperature thresholding in drug dispensing devices |
MA49897A (fr) | 2017-08-18 | 2020-06-24 | Amgen Inc | Injecteur sur-corps avec patch adhésif stérile |
WO2019046436A1 (en) * | 2017-08-31 | 2019-03-07 | Becton, Dickinson And Company | SYSTEM AND METHOD FOR DETECTING APPLIED FORCE DURING INJECTION |
EP3691716B1 (en) | 2017-10-06 | 2023-11-29 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
US11464903B2 (en) | 2017-10-09 | 2022-10-11 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
EP3703779A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
US20200261648A1 (en) * | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
MA50557A (fr) * | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
EP3710091A2 (en) * | 2017-11-14 | 2020-09-23 | Sanofi | Conserving power in an injection device |
KR20200096776A (ko) * | 2017-11-15 | 2020-08-13 | 데스박 | 약물 전달 장치 |
WO2019099324A1 (en) * | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
CN107998488A (zh) * | 2017-11-28 | 2018-05-08 | 广东嘉博制药有限公司 | 一种丁酸氯维地平脂肪乳注射液的输注系统 |
JP7203847B2 (ja) * | 2017-12-19 | 2023-01-13 | バイオコープ プロダクション ソシエテ アノニム | 自動注射薬物送出装置 |
CN111712285B (zh) * | 2017-12-21 | 2022-08-12 | 赛诺菲 | 确定注射状态 |
US11961600B2 (en) | 2017-12-21 | 2024-04-16 | Sanofi | Supplementary device for attachment to an injection device |
CN108154909A (zh) * | 2017-12-22 | 2018-06-12 | 广东康之家云健康医药股份有限公司 | 一种顾客药耗跟踪系统 |
EP3735286A4 (en) | 2018-01-03 | 2021-03-03 | Irenix Medical, Inc. | DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS WITH INTEGRATED PAIN RELIEF, AND THEIR METHODS FOR USE |
US11071831B2 (en) | 2018-02-22 | 2021-07-27 | Eli Lilly And Company | Dose detection system module for medication delivery device |
US11058605B2 (en) * | 2018-03-08 | 2021-07-13 | Flex Ltd. | Sterilization fluid path with barrier removal |
DK201870599A1 (en) | 2018-03-12 | 2019-10-16 | Apple Inc. | USER INTERFACES FOR HEALTH MONITORING |
ES2956287T3 (es) * | 2018-03-30 | 2023-12-18 | Amgen Inc | Inspección de contenedores de fármacos mediante cámaras |
EP4344715A2 (en) | 2018-04-19 | 2024-04-03 | Eli Lilly and Company | Status sensing system for injection device |
US11278670B2 (en) * | 2018-04-26 | 2022-03-22 | Carefusion 303, Inc. | Semi-autonomous hot-swap infusion module |
US11317833B2 (en) | 2018-05-07 | 2022-05-03 | Apple Inc. | Displaying user interfaces associated with physical activities |
DK201870380A1 (en) | 2018-05-07 | 2020-01-29 | Apple Inc. | DISPLAYING USER INTERFACES ASSOCIATED WITH PHYSICAL ACTIVITIES |
US11664107B2 (en) * | 2018-05-08 | 2023-05-30 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods using a prescription-regulated software application |
EP3793645A4 (en) * | 2018-05-15 | 2022-03-02 | QuiO Technologies LLC | SYSTEMS AND METHODS FOR DELIVERING A SUBSTANCE TO A LIVING BEING |
KR20200021794A (ko) * | 2018-08-21 | 2020-03-02 | 삼성전자주식회사 | 전자 장치의 제어 방법 및 이를 수행하기 위한 프로그램을 저장하는 컴퓨터 판독 기록 매체 |
US11324887B2 (en) * | 2018-09-14 | 2022-05-10 | Datadose, Llc | Reporting syringe |
JP2022502180A (ja) * | 2018-09-28 | 2022-01-11 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | ペン注射器用ユニバーサルスマートキャップ |
EP4059548A1 (en) * | 2018-10-03 | 2022-09-21 | Eli Lilly and Company | Status sensing systems within an injection device assembly |
EP3744368A1 (en) | 2018-10-05 | 2020-12-02 | Sorrel Medical Ltd. | Triggering sequence |
US10705891B2 (en) * | 2018-10-26 | 2020-07-07 | International Business Machines Corporation | Cognitive agent for persistent multi-platform reminder provision |
KR102623506B1 (ko) * | 2018-11-14 | 2024-01-11 | 메디허브 주식회사 | 자동주사장치 및 그 제어방법 |
CN109472515A (zh) * | 2018-11-26 | 2019-03-15 | 复旦大学附属中山医院 | 一种用于保障冷藏药品质量安全的监控方法及系统 |
WO2020132537A1 (en) | 2018-12-20 | 2020-06-25 | Skyland Analytics Inc. | Dynamic batch limit validation |
EP3972672A4 (en) | 2019-05-20 | 2023-06-21 | Unomedical A/S | ROTATING INFUSION DEVICE AND METHOD THEREOF |
US11152100B2 (en) | 2019-06-01 | 2021-10-19 | Apple Inc. | Health application user interfaces |
DK201970534A1 (en) | 2019-06-01 | 2021-02-16 | Apple Inc | User interfaces for monitoring noise exposure levels |
US11234077B2 (en) | 2019-06-01 | 2022-01-25 | Apple Inc. | User interfaces for managing audio exposure |
US11209957B2 (en) | 2019-06-01 | 2021-12-28 | Apple Inc. | User interfaces for cycle tracking |
US11228835B2 (en) | 2019-06-01 | 2022-01-18 | Apple Inc. | User interfaces for managing audio exposure |
US11094407B2 (en) * | 2019-06-13 | 2021-08-17 | International Business Machines Corporation | Electronics miniaturization platform for medication verification and tracking |
AU2020298084A1 (en) * | 2019-06-20 | 2021-11-04 | Amgen Inc. | Wireless communication enabled drug delivery device and method |
WO2021007355A1 (en) * | 2019-07-10 | 2021-01-14 | Verily Life Sciences Llc | Systems and methods for wearable emergency drug injection devices |
CN112057705B (zh) * | 2019-07-30 | 2023-04-18 | 嘉兴森迈医疗科技有限公司 | 注射装置 |
EP4007625A1 (en) * | 2019-08-01 | 2022-06-08 | Amgen Inc. | Drug delivery device with temperature measurement and related method |
EP4004702A1 (en) | 2019-09-09 | 2022-06-01 | Apple Inc. | Research study user interfaces |
JP2022547540A (ja) * | 2019-09-11 | 2022-11-14 | アルタヴィズ,リミティッド・ライアビリティ・カンパニー | ドーズガイダンス付きマイクロボリューム注射器と使用方法 |
WO2021059200A1 (en) * | 2019-09-25 | 2021-04-01 | Janssen Pharmaceuticals, Inc. | Drug delivery systems and methods |
JP2022550729A (ja) * | 2019-09-25 | 2022-12-05 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 薬物投与に関連付けられたパラメータの測定、及びそれを組み込んだ薬物投与デバイス |
CA3155914A1 (en) * | 2019-09-25 | 2021-04-01 | Janssen Pharmaceuticals, Inc. | DRUG DELIVERY SETTING |
MX2022003646A (es) * | 2019-09-25 | 2022-07-12 | Janssen Pharmaceuticals Inc | Interconexión de sistemas de administración de fármaco. |
CN114144216B (zh) * | 2019-10-01 | 2023-12-19 | 艾斯曲尔医疗公司 | 护帽组件 |
CN110841149A (zh) * | 2019-12-18 | 2020-02-28 | 苏州嘉树医疗科技有限公司 | 一种低温锁定的自动注射器 |
CN114727783A (zh) * | 2019-12-23 | 2022-07-08 | 费森尤斯医疗保健控股公司 | 用于促红细胞生成素刺激剂的连接的药物输送系统 |
US20230081468A1 (en) | 2020-03-11 | 2023-03-16 | Shl Medical Ag | System for evaluating a batch of medicament delivery devices, and method |
CA3077844A1 (en) * | 2020-04-03 | 2021-10-03 | Duoject Medical Systems Inc. | Method of sanitizing a medical device |
DE102020110112A1 (de) * | 2020-04-10 | 2021-10-14 | Fresenius Medical Care Deutschland Gmbh | Medizinisches Set für Kanülierung |
US11607216B2 (en) * | 2020-05-06 | 2023-03-21 | Janssen Pharmaceuticals, Inc. | Adaptive responses from smart packaging of drug delivery absorbable adjuncts |
US20210345953A1 (en) * | 2020-05-06 | 2021-11-11 | Janssen Pharmaceuticals, Inc. | Monitoring and communicating information using drug administration devices |
DK181037B1 (en) | 2020-06-02 | 2022-10-10 | Apple Inc | User interfaces for health applications |
USD955566S1 (en) | 2020-07-01 | 2022-06-21 | Zealand Pharma A/S | Medicament delivery device |
WO2022032024A1 (en) * | 2020-08-07 | 2022-02-10 | West Pharmaceutical Services, Inc. | Injection device and method of indicating an injection status for an injection device |
WO2022046991A1 (en) * | 2020-08-27 | 2022-03-03 | Insulet Corporation | Systems and methods for activating drug delivery devices |
US11698710B2 (en) | 2020-08-31 | 2023-07-11 | Apple Inc. | User interfaces for logging user activities |
WO2022059944A1 (ko) * | 2020-09-16 | 2022-03-24 | 이오플로우(주) | 니들 어셈블리 및 이를 포함하는 약액 주입 장치 |
US11737954B1 (en) | 2020-10-06 | 2023-08-29 | Verily Life Sciences Llc | Network-connected containers having medication stored therein |
US20220222734A1 (en) * | 2020-12-21 | 2022-07-14 | Beta Bionics, Inc. | Cloud-connected ambulatory pump integration |
US11464902B1 (en) | 2021-02-18 | 2022-10-11 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with compressible reservoir and method of use thereof |
US11311666B1 (en) | 2021-02-18 | 2022-04-26 | Fresenius Kabi Deutschland Gmbh | Modular wearable medicament delivery device and method of use thereof |
US11872369B1 (en) | 2021-02-18 | 2024-01-16 | Fresenius Kabi Deutschland Gmbh | Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof |
US11497847B1 (en) | 2021-02-19 | 2022-11-15 | Fresenius Kabi Deutschland Gmbh | Wearable injector with adhesive substrate |
US11607505B1 (en) | 2021-02-19 | 2023-03-21 | Fresenius Kabi Deutschland Gmbh | Wearable injector with sterility sensors |
US11633537B1 (en) | 2021-02-19 | 2023-04-25 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including a pre-filled cartridge |
US11344682B1 (en) | 2021-02-19 | 2022-05-31 | Fresenius Kabi Deutschland Gmbh | Drug supply cartridge with visual use indicator and delivery devices that use the same |
US11413394B1 (en) | 2021-02-19 | 2022-08-16 | Fresenius Kabi Deutschland Gmbh | Display for wearable drug delivery device |
US11426523B1 (en) | 2021-02-19 | 2022-08-30 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including a removable cartridge |
US11406755B1 (en) | 2021-02-19 | 2022-08-09 | Fresenius Kabi Deutschland Gmbh | Sensing fluid flow irregularities in an on-body injector |
US11896226B2 (en) | 2021-03-30 | 2024-02-13 | Cilag Gmbh International | Compressible adjuncts with healing-dependent degradation profile |
US11504125B2 (en) | 2021-03-30 | 2022-11-22 | Cilag Gmbh International | Tissue thickness compensating adjuncts having regions of differential expansion |
US11850332B2 (en) | 2021-03-30 | 2023-12-26 | Cilag Gmbh International | Method for treating tissue |
US11839374B2 (en) | 2021-03-30 | 2023-12-12 | Cilag Gmbh International | Compressible adjuncts with drug release features |
US11627961B2 (en) | 2021-03-30 | 2023-04-18 | Cilag Gmbh International | Compressible adjuncts with different behavioral zones |
US11849950B2 (en) | 2021-03-30 | 2023-12-26 | Cilag Gmbh International | Compressible adjuncts with drug dosage control features |
US11864765B2 (en) | 2021-03-30 | 2024-01-09 | Cilag Gmbh International | Compressible adjuncts with fluid control features |
US11602341B2 (en) | 2021-03-30 | 2023-03-14 | Cilag Gmbh International | Compressible adjuncts with drug release features |
US20220313256A1 (en) * | 2021-03-30 | 2022-10-06 | Cilag Gmbh International | Passively powered packaging for tissue adjuncts |
US11786240B2 (en) | 2021-03-30 | 2023-10-17 | Cilag Gmbh International | Using smart packaging in adjusting use of tissue adjuncts |
JP2022157793A (ja) | 2021-03-31 | 2022-10-14 | 三菱重工業株式会社 | 制御システム、処理装置および制御方法 |
EP4070832A1 (en) | 2021-04-07 | 2022-10-12 | medmix Switzerland AG | Keyed connectors |
US11504470B1 (en) | 2021-04-30 | 2022-11-22 | Fresenius Kabi Deutschland Gmbh | Deformable drug reservoir for wearable drug delivery device |
US11419976B1 (en) | 2021-04-30 | 2022-08-23 | Fresenius Kabi Deutschland Gmbh | Wearable drug delivery device with pressurized fluid dispensing |
US11529459B1 (en) | 2021-04-30 | 2022-12-20 | Fresenius Kabi Deutschland Gmbh | Wearable injector with adhesive module |
US11351300B1 (en) | 2021-04-30 | 2022-06-07 | Fresenius Kabl Deutschland GmbH | Drug dispensing system with replaceable drug supply cartridges |
US11717608B1 (en) | 2021-05-03 | 2023-08-08 | Fresenius Kabi Deutschland Gmbh | Drug delivery assembly including an adhesive pad |
US11484646B1 (en) | 2021-05-04 | 2022-11-01 | Fresenius Kabi Deutschland Gmbh | Sealing systems for a reservoir of an on-body injector |
WO2023276090A1 (ja) * | 2021-06-30 | 2023-01-05 | シンクランド株式会社 | 経皮投与装置及び経皮投与システム |
USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
WO2023147158A1 (en) * | 2022-01-31 | 2023-08-03 | Noble International, Llc | Interrogatable delivery device and associated status module |
GB2612154C (en) * | 2022-04-14 | 2023-11-08 | Kilnmark Ltd | Medication auto-injectors |
WO2023239948A1 (en) * | 2022-06-10 | 2023-12-14 | Alucent Biomedical Inc. | Sterilizable nvs catheter and light fiber for use therewith and methods of sterilization |
DE202023107090U1 (de) | 2022-12-01 | 2024-01-24 | Nuova Ompi S.R.L. Unipersonale | Vorrichtung zur subkutanen Verabreichung eines Medikaments |
Family Cites Families (427)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241704B1 (en) | 1901-11-22 | 2001-06-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US3485239A (en) * | 1967-11-02 | 1969-12-23 | Becton Dickinson Co | Self-contained sterile syringe |
US4386606A (en) | 1979-12-26 | 1983-06-07 | Waters Instruments, Inc. | Syringe lock |
IN155982B (ja) | 1980-12-31 | 1985-04-20 | Choi Soo Bong | |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4559038A (en) | 1984-10-19 | 1985-12-17 | Deltec Systems, Inc. | Drug delivery system |
US4654034A (en) * | 1986-02-03 | 1987-03-31 | Masters Edwin J | Safety needle cap |
US5222362A (en) | 1989-01-10 | 1993-06-29 | Maus Daryl D | Heat-activated drug delivery system and thermal actuators therefor |
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
WO1991005867A1 (en) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
AU7323994A (en) * | 1993-07-13 | 1995-02-13 | Sims Deltec, Inc. | Medical pump and method of programming |
CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5582593A (en) | 1994-07-21 | 1996-12-10 | Hultman; Barry W. | Ambulatory medication delivery system |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
IE77523B1 (en) | 1995-09-11 | 1997-12-17 | Elan Med Tech | Medicament delivery device |
ZA9610374B (en) | 1995-12-11 | 1997-06-23 | Elan Med Tech | Cartridge-based drug delivery device |
US5879143A (en) | 1996-04-26 | 1999-03-09 | Sims Deltec, Inc. | Reservoir enclosure adaptors and methods |
US6355019B1 (en) | 1996-12-18 | 2002-03-12 | Science Incorporated | Variable rate infusion apparatus with indicator and adjustable rate control |
US6183441B1 (en) | 1996-12-18 | 2001-02-06 | Science Incorporated | Variable rate infusion apparatus with indicator and adjustable rate control |
US20010039397A1 (en) | 1996-12-18 | 2001-11-08 | Kriesell Marshall S. | Fluid delivery apparatus with flow indicator and vial fill |
US6176845B1 (en) | 1996-12-18 | 2001-01-23 | Science Incorporated | Fluid delivery apparatus with flow indicator and vial fill |
US5991655A (en) * | 1997-03-03 | 1999-11-23 | Drug Delivery Systems, Inc. | Iontophoretic drug delivery device and method of manufacturing the same |
US6186982B1 (en) * | 1998-05-05 | 2001-02-13 | Elan Corporation, Plc | Subcutaneous drug delivery device with improved filling system |
WO1999003887A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
KR100641969B1 (ko) | 1997-07-23 | 2006-11-06 | 로셰 디아그노스틱스 게엠베하 | 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법 |
US6171276B1 (en) * | 1997-08-06 | 2001-01-09 | Pharmacia & Upjohn Ab | Automated delivery device and method for its operation |
SE9702872D0 (sv) * | 1997-08-06 | 1997-08-06 | Pharmacia & Upjohn Ab | Automated delivery device and method for its operation |
US5957895A (en) | 1998-02-20 | 1999-09-28 | Becton Dickinson And Company | Low-profile automatic injection device with self-emptying reservoir |
US6030086A (en) | 1998-03-02 | 2000-02-29 | Becton, Dickinson And Company | Flash tube reflector with arc guide |
AU3050499A (en) | 1998-03-23 | 1999-10-18 | Elan Corporation, Plc | Drug delivery device |
US6310078B1 (en) | 1998-04-20 | 2001-10-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
US8480580B2 (en) * | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
JP4087563B2 (ja) | 1998-06-15 | 2008-05-21 | ジーティーシー バイオセラピューティックス インコーポレイテッド | エリスロポエチン類似体−ヒト血清アルブミン融合物 |
US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
DE19840965A1 (de) * | 1998-09-08 | 2000-03-09 | Disetronic Licensing Ag | Vorrichtung zur Selbstverabreichung eines Produktfluids |
EP1124961B9 (en) | 1998-10-23 | 2010-07-21 | Kirin-Amgen Inc. | Thrombopoietic compounds |
SI1813624T1 (sl) | 1998-10-23 | 2010-12-31 | Amgen Inc | Postopki in sestavki za prepeäśevanje in zdravljenje anemije |
US7766873B2 (en) | 1998-10-29 | 2010-08-03 | Medtronic Minimed, Inc. | Method and apparatus for detecting occlusions in an ambulatory infusion pump |
US7621893B2 (en) | 1998-10-29 | 2009-11-24 | Medtronic Minimed, Inc. | Methods and apparatuses for detecting occlusions in an ambulatory infusion pump |
PT1133558E (pt) | 1998-11-27 | 2007-01-31 | Ucb Sa | Composições e métodos para aumentar a mineralização óssea |
EP1006184A1 (en) | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
WO2000061637A1 (en) | 1999-04-14 | 2000-10-19 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
JP2003512840A (ja) | 1999-10-22 | 2003-04-08 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ラット脳に由来する核酸分子およびプログラム細胞死モデル |
US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
EP1252323B1 (en) | 2000-01-21 | 2005-12-07 | BioVex Limited | Virus strains for the oncolytic treatment of cancer |
US6813519B2 (en) | 2000-01-21 | 2004-11-02 | Medtronic Minimed, Inc. | Ambulatory medical apparatus and method using a robust communication protocol |
US20010049608A1 (en) | 2000-01-25 | 2001-12-06 | Hochman Mark N. | Injection tracking and management system |
AUPQ599700A0 (en) | 2000-03-03 | 2000-03-23 | Super Internet Site System Pty Ltd | On-line geographical directory |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
EP1961425B1 (en) | 2000-04-21 | 2017-07-19 | Amgen Inc. | Methods and erythropoeitin analogs for the prevention and treatment of anemia |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US6968179B1 (en) | 2000-07-27 | 2005-11-22 | Microsoft Corporation | Place specific buddy list services |
US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
GB2366705B (en) | 2000-08-29 | 2004-07-14 | Motorola Inc | Communications system, communications unit and method of operation |
JP2004521667A (ja) | 2000-09-08 | 2004-07-22 | インシュレット コーポレイション | 患者の輸液のための装置、システム及び方法 |
KR20030046411A (ko) | 2000-09-08 | 2003-06-12 | 그리폰 테라퓨틱스, 인코포레이티드 | '위'-천연 화학적 라이게이션 |
AU2001289589A1 (en) * | 2000-09-22 | 2002-04-02 | Novo-Nordisk A/S | A medication delivery device |
EP1332440B1 (en) | 2000-10-04 | 2012-04-11 | Insulet Corporation | Data collection assembly for patient infusion system |
US7271689B1 (en) | 2000-11-22 | 2007-09-18 | Fonar Corporation | Magnet structure |
DE60144439D1 (de) | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
ATE464322T1 (de) | 2001-01-05 | 2010-04-15 | Pfizer | Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i |
WO2002056822A1 (en) * | 2001-01-19 | 2002-07-25 | Raimo Juselius | Device for monitoring the administration of doses and system for monitoring the administration of doses |
ATE435923T1 (de) | 2001-04-04 | 2009-07-15 | Genodyssee | Neue polynukleotide und polypeptide des erythropoietingens |
US6817986B2 (en) * | 2001-04-13 | 2004-11-16 | Avant Medical Corp. | Jet injector with data logging system for use in compliance and dose monitoring programs |
ES2387546T3 (es) | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
US20120209197A1 (en) | 2002-01-04 | 2012-08-16 | Lanigan Richard J | Infusion pump assembly |
US8034026B2 (en) | 2001-05-18 | 2011-10-11 | Deka Products Limited Partnership | Infusion pump assembly |
ES2907826T3 (es) | 2001-06-26 | 2022-04-26 | Amgen Inc | Anticuerpos para OPGL |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
CA2456648C (en) | 2001-08-23 | 2011-08-16 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
US6930086B2 (en) | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US7204823B2 (en) | 2001-12-19 | 2007-04-17 | Medtronic Minimed, Inc. | Medication delivery system and monitor |
WO2003055526A2 (en) | 2001-12-21 | 2003-07-10 | Maxygen Aps | Erythropoietin conjugates |
DK1461359T3 (da) | 2002-01-18 | 2007-07-09 | Pf Medicament | Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
WO2003064664A1 (en) | 2002-01-31 | 2003-08-07 | Oxford Biomedica (Uk) Limited | Physiologically regulated erythropoietin- exprressing vector for the treatment of anaemia |
GB0202252D0 (en) | 2002-01-31 | 2002-03-20 | Oxford Biomedica Ltd | Anemia |
US7004928B2 (en) * | 2002-02-08 | 2006-02-28 | Rosedale Medical, Inc. | Autonomous, ambulatory analyte monitor or drug delivery device |
CN100418588C (zh) | 2002-02-18 | 2008-09-17 | 丹福斯有限公司 | 用来对流体形式的药物进行给药的装置 |
US6918894B2 (en) | 2002-02-28 | 2005-07-19 | Medical Product Specialists | Huber needle with anti-rebound safety mechanism |
US20050027264A1 (en) | 2002-02-28 | 2005-02-03 | Fleury Michael T. | Huber needle with anti-rebound safety mechanism |
US7033338B2 (en) | 2002-02-28 | 2006-04-25 | Smiths Medical Md, Inc. | Cartridge and rod for axially loading medication pump |
US6878136B2 (en) | 2002-02-28 | 2005-04-12 | Medical Product Specialists | Huber needle with anti-rebound safety mechanism |
WO2003080852A1 (en) | 2002-03-26 | 2003-10-02 | Lek Pharmaceutical And Chemical Company D.D. | Process for the preparation of a desired erythropoietin glyco-isoform profile |
AU2003222069A1 (en) | 2002-03-29 | 2003-10-20 | Centocor, Inc. | Mammalian cdr mimetibodies, compositions, methods and uses |
CN102212537B (zh) | 2002-03-29 | 2013-08-14 | 组合化学工业株式会社 | 编码乙酰乳酸合酶的基因 |
US6656158B2 (en) | 2002-04-23 | 2003-12-02 | Insulet Corporation | Dispenser for patient infusion device |
US6960192B1 (en) * | 2002-04-23 | 2005-11-01 | Insulet Corporation | Transcutaneous fluid delivery system |
US6656159B2 (en) | 2002-04-23 | 2003-12-02 | Insulet Corporation | Dispenser for patient infusion device |
CA2485365A1 (en) | 2002-05-13 | 2003-11-20 | Modigenetech Ltd. | Ctp-extended erythropoietin |
EP2316922B1 (en) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
AU2003280130B2 (en) | 2002-06-28 | 2009-06-11 | Centocor, Inc. | Mammalian CH1 deleted mimetibodies, compositions, methods and uses |
BR0312276A (pt) | 2002-06-28 | 2005-04-26 | Centocor Inc | Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos |
EP3610909A1 (en) | 2002-07-02 | 2020-02-19 | PHC Holdings Corporation | Automatic administration instrument for medical use |
US7018360B2 (en) | 2002-07-16 | 2006-03-28 | Insulet Corporation | Flow restriction system and method for patient infusion device |
WO2004009627A1 (en) | 2002-07-19 | 2004-01-29 | Cangene Corporation | Pegylated erythropoietic compounds |
JP4406607B2 (ja) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
CA2495238A1 (en) | 2002-08-26 | 2004-03-04 | Penjet Corporation | Apparatus for needle-less injection with a degassed fluid |
MEP32508A (en) | 2002-09-06 | 2010-10-10 | Amgen Inc | Therapeutic human anti-il-1r1 monoclonal antibody |
PL217085B1 (pl) | 2002-09-11 | 2014-06-30 | Fresenius Kabi Gmbh | Koniugat hydroksyalkiloskrobi i polipeptydu, sposób wytwarzania koniugatu hydroksyalkiloskrobi i polipeptydu, zastosowanie koniugatu hydroksyalkiloskrobi i polipeptydu oraz kompozycja farmaceutyczna koniugatu hydroksyalkiloskrobi i polipeptydu |
EP1545661A2 (en) | 2002-09-12 | 2005-06-29 | Children's Hospital Medical Center | Method and device for painless injection of medication |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
US7144384B2 (en) | 2002-09-30 | 2006-12-05 | Insulet Corporation | Dispenser components and methods for patient infusion device |
US7128727B2 (en) | 2002-09-30 | 2006-10-31 | Flaherty J Christopher | Components and methods for patient infusion device |
US20050075670A1 (en) | 2002-10-07 | 2005-04-07 | Henrik Bengtsson | Signal device with electro-muscle stimulation feature |
TWI320716B (en) | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
US7396913B2 (en) | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
WO2004034988A2 (en) | 2002-10-16 | 2004-04-29 | Amgen Inc. | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
KR20150013350A (ko) | 2002-12-20 | 2015-02-04 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
RU2004132832A (ru) | 2003-03-06 | 2005-08-27 | Лайфскен, Инк. (Us) | Система и способ для прокалывания дермальной ткани |
BRPI0408317A (pt) | 2003-03-14 | 2006-03-07 | Pharmacia Corp | anticorpos do receptor de igf-i para o tratamento de cáncer |
EP1613658B1 (en) | 2003-04-02 | 2012-03-14 | F. Hoffmann-La Roche AG | Antibodies against insulin-like growth factor i receptor and uses thereof |
CA2520880A1 (en) * | 2003-04-18 | 2004-11-04 | Insulet Corporation | User interface for infusion pump remote controller and method of using the same |
US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
BRPI0409658A (pt) * | 2003-04-23 | 2006-04-18 | Vasogen Ireland Ltd | sistemas de distribuição |
CA2524305C (en) | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
EP2336162A1 (en) | 2003-05-12 | 2011-06-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
SI1629007T1 (sl) | 2003-05-12 | 2009-10-31 | Affymax Inc | Novi peptidi, ki se veĹľejo na eritropoetinski receptor |
ES2395413T3 (es) | 2003-05-12 | 2013-02-12 | Affymax, Inc. | Péptidos que se unen al receptor de eritropoyetina |
US7074755B2 (en) | 2003-05-17 | 2006-07-11 | Centocor, Inc. | Erythropoietin conjugate compounds with extended half-lives |
CA2527665A1 (en) | 2003-05-30 | 2004-12-16 | Centocor, Inc. | Formation of novel erythropoietin conjugates using transglutaminase |
DE10325106A1 (de) | 2003-06-03 | 2004-12-30 | Disetronic Licensing Ag | Vorrichtung und Verfahren zur Erkennung eines Benutzers eines medizinischen Geräts |
US20050037390A1 (en) | 2003-06-04 | 2005-02-17 | Irm Llc, A Delaware Limited Liability Company | Methods and compositions for modulating erythropoietin expression |
WO2005000384A1 (en) | 2003-06-05 | 2005-01-06 | University Of Florida | Auto-injection devices and methods for intramuscular administration of medications |
US20050020980A1 (en) | 2003-06-09 | 2005-01-27 | Yoshio Inoue | Coupling system for an infusion pump |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
MEP31408A (en) | 2003-07-18 | 2010-10-10 | Abgenix Inc | Specific binding agents to hepatocyte growth factor |
US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
SG145737A1 (en) | 2003-08-12 | 2008-09-29 | Becton Dickinson Co | Patch-like infusion device |
US20070275871A1 (en) | 2003-08-28 | 2007-11-29 | Biorexis Technology, Inc. | Epo Mimetic Peptides and Fusion Proteins |
CN1882355A (zh) | 2003-09-09 | 2006-12-20 | 沃伦药品公司 | 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 |
UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
US20060127404A1 (en) | 2003-09-30 | 2006-06-15 | Chichi Huang | Hinge core mimetibodies, compositions, methods and uses |
CA2511746C (en) | 2003-11-06 | 2013-03-26 | Lifescan, Inc. | Drug delivery pen with event notification means |
TWI356064B (en) | 2003-11-07 | 2012-01-11 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
AU2004293103C1 (en) | 2003-11-24 | 2010-12-02 | Ratiopharm Gmbh | Glycopegylated erythropoietin |
WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
EP1548031A1 (en) | 2003-12-22 | 2005-06-29 | Dubai Genetics FZ-LLC | Nature-identical erythropoietin |
WO2005065239A2 (en) | 2003-12-31 | 2005-07-21 | Centocor, Inc. | Novel recombinant proteins with n-terminal free thiol |
KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 |
US7423139B2 (en) | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
US20050187158A1 (en) | 2004-01-22 | 2005-08-25 | Ranby Mats G. | Pharmaceutical composition |
WO2005084711A1 (fr) | 2004-03-02 | 2005-09-15 | Chengdu Institute Of Biological Products | Erythropoietine recombinante pegylee a activite in vivo |
WO2005092369A2 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyethyl starch and erythropoietin |
MXPA06010887A (es) | 2004-03-23 | 2007-03-08 | Amgen Inc | Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano. |
US20050227289A1 (en) | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
JP2008508854A (ja) | 2004-04-23 | 2008-03-27 | ケンブリッジ アンティボディー テクノロジー リミテッド | エリスロポイエチンタンパク質変異体 |
US7220245B2 (en) | 2004-05-26 | 2007-05-22 | Kriesel Marshall S | Infusion apparatus |
PL1781697T3 (pl) | 2004-07-07 | 2009-10-30 | H Lundbeck As | Nowa karbamylowana EPO i sposób jej wytwarzania |
FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
US20060073563A1 (en) | 2004-09-02 | 2006-04-06 | Xencor, Inc. | Erythropoietin derivatives with altered immunogenicity |
EP1640029A1 (en) | 2004-09-24 | 2006-03-29 | Novo Nordisk A/S | Injection device with cap |
CA2586915A1 (en) | 2004-11-10 | 2006-05-18 | Aplagen Gmbh | Molecules which promote hematopoiesis |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
EP1830699A2 (en) | 2004-12-22 | 2007-09-12 | Novo Nordisk A/S | Sensor system and method for detecting problems with mounting of skin mountable medical devices |
EP1841455A1 (en) | 2005-01-24 | 2007-10-10 | Amgen Inc. | Humanized anti-amyloid antibody |
US8231573B2 (en) * | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
US8226610B2 (en) | 2005-02-01 | 2012-07-24 | Intelliject, Inc. | Medical injector with compliance tracking and monitoring |
JP4948422B2 (ja) * | 2005-02-01 | 2012-06-06 | インテリジェクト,インコーポレイテッド | 薬物送出の装置、システムおよび方法 |
US8361026B2 (en) | 2005-02-01 | 2013-01-29 | Intelliject, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
US8147451B2 (en) | 2005-02-11 | 2012-04-03 | Stryker Corporation | Reprogrammable fluid delivery system and method of use |
US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
EP1881820B1 (en) | 2005-05-17 | 2020-06-17 | Roche Diabetes Care GmbH | Disposable dispenser for patient infusion |
US20060263839A1 (en) | 2005-05-17 | 2006-11-23 | Isense Corporation | Combined drug delivery and analyte sensor apparatus |
US9457147B2 (en) | 2005-06-16 | 2016-10-04 | Novo Nordisk A/S | Method and apparatus for assisting patients in self-administration of medication |
KR101246504B1 (ko) | 2005-06-17 | 2013-03-26 | 임클론 엘엘씨 | 항-PDGFRα 항체 |
JP2008543500A (ja) | 2005-06-21 | 2008-12-04 | イーライ リリー アンド カンパニー | 医薬品注射用の器具及び方法 |
WO2007000328A1 (en) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
NZ625807A (en) | 2005-07-18 | 2015-11-27 | Amgen Inc | Human anti-b7rp1 neutralizing antibodies |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
US20070038181A1 (en) | 2005-08-09 | 2007-02-15 | Alexander Melamud | Method, system and device for delivering a substance to tissue |
US20070060870A1 (en) | 2005-08-16 | 2007-03-15 | Tolle Mike Charles V | Controller device for an infusion pump |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
WO2007035666A2 (en) | 2005-09-19 | 2007-03-29 | Lifescan, Inc. | Electrokinetic infusion pump system |
DE102005052502A1 (de) | 2005-11-03 | 2007-05-16 | Tecpharma Licensing Ag | Autoinjektor-Aktivierung Auslöseelement |
US7935104B2 (en) * | 2005-11-07 | 2011-05-03 | Medingo, Ltd. | Systems and methods for sustained medical infusion and devices related thereto |
US20150057615A1 (en) | 2005-11-08 | 2015-02-26 | Asante Solutions | Infusion Pump System |
US7988660B2 (en) | 2005-12-20 | 2011-08-02 | Eli Lilly And Company | Needle-free injection device |
EP2713517B1 (en) * | 2006-01-31 | 2018-01-03 | Ares Trading S.A. | Injection device with a capacitive proximity sensor |
CN109621078B (zh) | 2006-02-09 | 2022-05-27 | 德卡产品有限公司 | 用于控制可配戴医疗器件的系统 |
US9839743B2 (en) | 2006-02-09 | 2017-12-12 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
GB0603683D0 (en) | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
JP5197566B2 (ja) | 2006-03-20 | 2013-05-15 | ノボ・ノルデイスク・エー/エス | 注射針の位置決定 |
GB2477046B (en) | 2006-03-29 | 2011-08-24 | Intelliject Inc | Devices,systems and methods for medicament delivery |
TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之c-kit抗體 |
US8348885B2 (en) * | 2006-04-28 | 2013-01-08 | Medtronic Minimed, Inc. | Remote monitoring for networked fluid infusion systems |
US7871399B2 (en) | 2006-05-17 | 2011-01-18 | Alcon Research, Ltd. | Disposable ophthalmic injection device |
WO2007136752A2 (en) | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Erythropoietin compositions |
US20070282269A1 (en) | 2006-05-31 | 2007-12-06 | Seattle Medical Technologies | Cannula delivery apparatus and method for a disposable infusion device |
US9308325B2 (en) | 2006-06-19 | 2016-04-12 | Corium International, Inc. | Methods, devices, and kits for microjet drug delivery |
AU2007269791B2 (en) * | 2006-06-30 | 2013-10-03 | Abbvie Biotechnology Ltd | Automatic injection device |
US8044778B2 (en) | 2007-07-12 | 2011-10-25 | Henry Schein, Inc. | Injection device and case with reporting ability |
US7752085B2 (en) | 2006-07-13 | 2010-07-06 | Henry Schein, Inc. | Product information management system |
US20080160492A1 (en) | 2006-08-08 | 2008-07-03 | Insulet Corporation | Interactive training system and method |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
JP2010504798A (ja) | 2006-09-29 | 2010-02-18 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 経皮ドラッグデリバリーのための電気的に活性化されたゲル配列 |
US20080234625A1 (en) | 2006-10-16 | 2008-09-25 | Bruno Dacquay | Fuse Assembly For Single Use Medical Device |
US20110077614A1 (en) | 2006-10-19 | 2011-03-31 | Ofer Shay | Device and method for patient activated bolus administration |
WO2008057459A2 (en) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonists of pcsk9 |
US20100150937A1 (en) | 2006-11-07 | 2010-06-17 | Sparrow Carl P | Antagonists of pcsk9 |
CA2667989A1 (en) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonists of pcsk9 |
EP2083859A4 (en) | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
US20080119705A1 (en) | 2006-11-17 | 2008-05-22 | Medtronic Minimed, Inc. | Systems and Methods for Diabetes Management Using Consumer Electronic Devices |
KR20090088950A (ko) | 2006-12-14 | 2009-08-20 | 쉐링 코포레이션 | 가공된 항-tslp 항체 |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
IL185737A0 (en) | 2007-09-05 | 2008-01-06 | Sindolor Medical Ltd | A device and method for piercing a patient's skin with an injector whilst reducing pain caused by the piercing |
WO2008114218A2 (en) * | 2007-03-19 | 2008-09-25 | Insuline Medical Ltd. | Method and device for drug delivery |
EP2136863A2 (en) | 2007-03-19 | 2009-12-30 | Insuline Medical Ltd. | Device for drug delivery and associated connections thereto |
EP3461517A1 (de) | 2007-03-22 | 2019-04-03 | Tecpharma Licensing AG | Injektionsvorrichtung mit signalisierungseinheit |
TW200906439A (en) | 2007-04-13 | 2009-02-16 | Novartis Ag | Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9) |
CN101730555B (zh) | 2007-05-10 | 2012-11-07 | Medx-Set有限公司 | 输液器自闭塞机构 |
US7981102B2 (en) | 2007-05-21 | 2011-07-19 | Asante Solutions, Inc. | Removable controller for an infusion pump |
US7794426B2 (en) | 2007-05-21 | 2010-09-14 | Asante Solutions, Inc. | Infusion pump system with contamination-resistant features |
JP2010530233A (ja) | 2007-06-20 | 2010-09-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | アレルギー疾患を処置する方法および組成物 |
JP2010534085A (ja) | 2007-07-20 | 2010-11-04 | メディンゴ・リミテッド | 手動操作可能な携帯式注入装置 |
US8683381B2 (en) | 2007-08-09 | 2014-03-25 | Alfred E. Mann Foundation For Scientific Research | Drug delivery safety system |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US20090082730A1 (en) | 2007-09-24 | 2009-03-26 | Li Nguyen | Needle injection assembly |
US7771391B2 (en) | 2007-09-28 | 2010-08-10 | Calibra Medical, Inc. | Disposable infusion device with snap action actuation |
US8231572B2 (en) | 2007-09-28 | 2012-07-31 | Calibra Medical, Inc. | Disposable infusion device with reuse lock-out |
TWI451862B (zh) | 2007-10-09 | 2014-09-11 | Alcon Res Ltd | 用於眼睛注射的熱係數驅動藥丸尺寸 |
US20090099525A1 (en) | 2007-10-11 | 2009-04-16 | Animas Corporation | Drug Delivery System with Breakaway Plunger Extractor |
CN102232088A (zh) | 2007-10-26 | 2011-11-02 | 先灵公司 | 用于治疗脂类和胆固醇疾病的抗pcsk9及方法 |
WO2009059187A1 (en) * | 2007-11-02 | 2009-05-07 | University Of Virginia Patent Foundation | Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing |
US7875022B2 (en) | 2007-12-12 | 2011-01-25 | Asante Solutions, Inc. | Portable infusion pump and media player |
US8409133B2 (en) * | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US7976505B2 (en) | 2007-12-19 | 2011-07-12 | Calibra Medical, Inc. | Disposable infusion device negative pressure filling apparatus and method |
US10188787B2 (en) | 2007-12-31 | 2019-01-29 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
EP2359880A3 (en) * | 2008-02-04 | 2011-09-21 | Nilimedix Ltd. | Drug delivery system with wireless monitor |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
US8540673B2 (en) | 2008-03-18 | 2013-09-24 | Calibra Medical, Inc. | Disposable infusion device with actuation lock-out |
WO2009120692A2 (en) * | 2008-03-25 | 2009-10-01 | Animal Innovations, Inc. | Syringe mechanism for detecting syringe status |
JP5313236B2 (ja) * | 2008-04-10 | 2013-10-09 | パナソニック株式会社 | 薬剤投与装置 |
US20090259194A1 (en) | 2008-04-11 | 2009-10-15 | Raffi Pinedjian | Keyed Safety Cap and Receptacle for Two Piece Injection Device |
CA3142745A1 (en) * | 2008-05-20 | 2009-11-26 | Avant Medical Corp. | Autoinjector system |
US9295786B2 (en) | 2008-05-28 | 2016-03-29 | Medtronic Minimed, Inc. | Needle protective device for subcutaneous sensors |
US8361030B2 (en) | 2008-06-26 | 2013-01-29 | Calibra Medical, Inc. | Disposable infusion device with occlusion detector |
US7976500B2 (en) | 2008-06-26 | 2011-07-12 | Calibra Medical, Inc. | Disposable infusion device with redundant valved safety |
US8231577B2 (en) | 2008-06-26 | 2012-07-31 | Calibra Medical, Inc. | Disposable infusion device with automatically releasable cannula driver |
GB0814747D0 (en) | 2008-08-13 | 2008-09-17 | Owen Mumford Ltd | Autoinjection devices |
CA2734035C (en) | 2008-09-10 | 2014-05-06 | F. Hoffmann-La Roche Ag | Delivery device for use with a therapeutic drug |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
US9427529B2 (en) | 2008-09-15 | 2016-08-30 | Medimop Medical Projects Ltd. | Safeguard mechanism for autoinjector needle |
CA2738389C (en) * | 2008-09-15 | 2017-01-17 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
WO2010037828A1 (en) * | 2008-10-01 | 2010-04-08 | Novo Nordisk A/S | Medical assembly with monitoring device |
US20090192443A1 (en) * | 2008-10-06 | 2009-07-30 | Collins Jr James F | Ophthalmic fluid delivery device and method of operation |
US8223028B2 (en) | 2008-10-10 | 2012-07-17 | Deka Products Limited Partnership | Occlusion detection system and method |
US8262616B2 (en) | 2008-10-10 | 2012-09-11 | Deka Products Limited Partnership | Infusion pump assembly |
US8016789B2 (en) | 2008-10-10 | 2011-09-13 | Deka Products Limited Partnership | Pump assembly with a removable cover assembly |
US8597570B2 (en) | 2008-11-04 | 2013-12-03 | Panasonic Corporation | Measurement device, insulin infusion device, measurement method, method for controlling insulin infusion device, and program |
US20100121274A1 (en) | 2008-11-12 | 2010-05-13 | Baxter International Inc. | Prefillable constant pressure ambulatory infusion pump |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US9370621B2 (en) | 2008-12-16 | 2016-06-21 | Medtronic Minimed, Inc. | Needle insertion systems and methods |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
ES2709106T3 (es) * | 2009-02-27 | 2019-04-15 | Lifescan Inc | Sistemas y métodos de gestión de administración de fármacos |
US8496623B2 (en) | 2009-03-02 | 2013-07-30 | Becton, Dickinson And Company | Bi-directional cannula feature capture mechanism |
WO2010107761A1 (en) | 2009-03-18 | 2010-09-23 | Acelrx Pharmaceuticals, Inc. | Improved storage and dispensing devices for administration of oral transmucosal dosage forms |
DE102009002537A1 (de) | 2009-04-21 | 2010-10-28 | Robert Bosch Gmbh | Medizinische, von einem Patienten zu benutzende Vorrichtung |
US7976493B2 (en) | 2009-05-05 | 2011-07-12 | Calibra Medical, Inc. | Disposable infusion device with resettable last dose lock-out |
US20110125844A1 (en) * | 2009-05-18 | 2011-05-26 | Telcordia Technologies, Inc. | mobile enabled social networking application to support closed, moderated group interactions for purpose of facilitating therapeutic care |
US8777897B2 (en) | 2009-07-06 | 2014-07-15 | Carefusion 303, Inc. | Fluid delivery systems and methods having wireless communication |
US8344847B2 (en) | 2009-07-09 | 2013-01-01 | Medtronic Minimed, Inc. | Coordination of control commands in a medical device system having at least one therapy delivery device and at least one wireless controller device |
US8882710B2 (en) | 2009-09-02 | 2014-11-11 | Medtronic Minimed, Inc. | Insertion device systems and methods |
US10071198B2 (en) | 2012-11-02 | 2018-09-11 | West Pharma. Servicees IL, Ltd. | Adhesive structure for medical device |
EP2301611B1 (en) | 2009-09-25 | 2012-08-15 | Letcat Aktiebolag | Medical delivery device |
EP2480576A4 (en) | 2009-09-25 | 2013-04-10 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
US9035744B2 (en) | 2009-10-01 | 2015-05-19 | Blackberry Limited | Method and apparatus for monitoring and controlling a medical device using a wireless mobile communication device |
US7967773B2 (en) | 2009-10-13 | 2011-06-28 | Smiths Medical Asd, Inc. | Two piece medication cassette closure apparatus and method |
CN104474604B (zh) | 2009-10-13 | 2017-08-11 | 瓦莱里塔斯公司 | 流体输送装置 |
IN2012DN03824A (ja) | 2009-10-30 | 2015-08-28 | Merck Sharp & Dohme | |
AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
US8945066B2 (en) | 2009-11-06 | 2015-02-03 | Crisi Medical Systems, Inc. | Medication injection site and data collection system |
US8449504B2 (en) | 2009-11-11 | 2013-05-28 | Calibra Medical, Inc. | Wearable infusion device and system |
AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
EP2512579B1 (en) | 2009-12-16 | 2016-11-30 | Becton, Dickinson and Company | Self-injection device |
EP3527239B1 (en) | 2009-12-16 | 2021-01-27 | Becton, Dickinson and Company | Self-injection device |
CN102753234A (zh) | 2009-12-16 | 2012-10-24 | 贝克顿·迪金森公司 | 自注射装置 |
CN106955392B (zh) | 2009-12-16 | 2020-03-27 | 贝克顿·迪金森公司 | 药物传送装置 |
EP2512559B1 (en) | 2009-12-16 | 2018-12-05 | Becton, Dickinson and Company | Self-injection device |
US20110160696A1 (en) | 2009-12-31 | 2011-06-30 | Abbott Diabetes Care Inc. | Injection port device adapted for use with insulin pump |
US8070723B2 (en) | 2009-12-31 | 2011-12-06 | Medtronic Minimed, Inc. | Activity guard |
US10911515B2 (en) * | 2012-05-24 | 2021-02-02 | Deka Products Limited Partnership | System, method, and apparatus for electronic patient care |
CA2789141C (en) * | 2010-02-05 | 2018-06-12 | Deka Products Limited Partnership | Infusion pump apparatus, method and system |
US9662438B2 (en) * | 2010-02-05 | 2017-05-30 | Deka Products Limited Partnership | Devices, methods and systems for wireless control of medical devices |
JP5805111B2 (ja) | 2010-02-18 | 2015-11-04 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | トーションばねを備えた自動注射器 |
CN102802522B (zh) | 2010-02-25 | 2015-12-09 | 生命扫描苏格兰有限公司 | 具有胰岛素给药安全警告的分析物测试方法和系统 |
CN102844332B (zh) | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
TW201200190A (en) * | 2010-03-26 | 2012-01-01 | Sanofi Aventis Deutschland | Electro-mechanical drug delivery device |
US8285328B2 (en) * | 2010-04-20 | 2012-10-09 | Minipumps, Llc | Remote-controlled drug pump devices |
US20130184640A1 (en) | 2010-04-20 | 2013-07-18 | Minipumps, Llc | Accurate flow control in drug pump devices |
JP5809242B2 (ja) | 2010-04-21 | 2015-11-10 | アッヴィ バイオテクノロジー リミテッド | 治療薬の制御送達のための装着型自動注入装置 |
US9737659B2 (en) | 2010-05-12 | 2017-08-22 | Bioq Pharma Incorporated | Apparatus for dispensing medicinal fluids and method of making same |
US8821454B2 (en) | 2010-05-12 | 2014-09-02 | Bioquiddity, Inc. | Apparatus for dispensing medicinal fluids and method of making same |
EA024052B1 (ru) * | 2010-06-07 | 2016-08-31 | Эмджен Инк. | Устройство для доставки лекарственного средства |
US8676600B2 (en) * | 2010-08-12 | 2014-03-18 | Fenwal, Inc | Mobile applications for blood centers |
EP2605813B1 (en) * | 2010-08-17 | 2018-08-01 | University of Florida Research Foundation, Inc. | Intelligent drug delivery system to optimizing medical treatment or therapy. |
WO2012032411A2 (en) | 2010-09-07 | 2012-03-15 | Tecpharma Licensing Ag | Automatic injection device |
US20120066140A1 (en) | 2010-09-14 | 2012-03-15 | Nokia Corporation | Method and apparatus for monitoring adherence to prescribed regimens |
US8915879B2 (en) | 2010-09-24 | 2014-12-23 | Perqflo, Llc | Infusion pumps |
US9216249B2 (en) | 2010-09-24 | 2015-12-22 | Perqflo, Llc | Infusion pumps |
US9308320B2 (en) | 2010-09-24 | 2016-04-12 | Perqflo, Llc | Infusion pumps |
US9498573B2 (en) | 2010-09-24 | 2016-11-22 | Perqflo, Llc | Infusion pumps |
EP2438945A1 (en) | 2010-10-08 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Reusable engine for an auto-injector |
US8707392B2 (en) * | 2010-10-15 | 2014-04-22 | Roche Diagnostics Operations, Inc. | Systems and methods for disease management |
WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
US9211378B2 (en) | 2010-10-22 | 2015-12-15 | Cequr Sa | Methods and systems for dosing a medicament |
DK2635330T3 (en) | 2010-11-03 | 2016-04-04 | Sanofi Aventis Deutschland | Drug-module with locking device |
US8905972B2 (en) | 2010-11-20 | 2014-12-09 | Perqflo, Llc | Infusion pumps |
GB201020472D0 (en) * | 2010-12-02 | 2011-01-19 | Oval Medical Technologies Ltd | A drive assembly for an autoinjector |
GB201020475D0 (en) | 2010-12-02 | 2011-01-19 | Oval Medical Technologies Ltd | Delivery mechanism for an autoinjector |
DK2652652T3 (da) | 2010-12-17 | 2020-02-17 | Sanofi Aventis Deutschland | Medikmentadministration |
SG191219A1 (en) | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
KR102291972B1 (ko) * | 2011-01-19 | 2021-08-23 | 프랙틸 헬쓰, 인코포레이티드 | 조직의 치료를 위한 장치 및 방법 |
MX347602B (es) | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
WO2012109530A1 (en) | 2011-02-11 | 2012-08-16 | Irm Llc | Pcsk9 antagonists |
US8639288B1 (en) | 2011-02-22 | 2014-01-28 | Medavie Technologies | Injector device |
US10010273B2 (en) | 2011-03-10 | 2018-07-03 | Abbott Diabetes Care, Inc. | Multi-function analyte monitor device and methods of use |
EP3799907A1 (en) | 2011-03-24 | 2021-04-07 | Sanofi-Aventis Deutschland GmbH | Device and method for detecting an actuation action performable with a medical device |
DK2691131T3 (en) * | 2011-03-30 | 2015-11-16 | Sanofi Aventis Deutschland | Injection device |
EP2700424B1 (en) | 2011-04-19 | 2018-01-10 | Terumo Kabushiki Kaisha | Infusion pump |
JP6038884B2 (ja) * | 2011-04-20 | 2016-12-07 | アムゲン・インコーポレーテッド | 自動式注射装置 |
EP3020428A1 (en) | 2011-04-21 | 2016-05-18 | AbbVie Inc. | Wearable automatic injection device for controlled administration of therapeutic agents |
EP2705453B1 (en) | 2011-05-06 | 2018-12-19 | Novo Nordisk A/S | System for optimizing a drug dosage regimen over time |
EP2707059A2 (en) | 2011-05-10 | 2014-03-19 | Insuline Medical Ltd. | Device, system and method for facilitating syringe based drug delivery and management thereof |
JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
CN103796696B (zh) * | 2011-05-25 | 2016-02-03 | 赛诺菲-安万特德国有限公司 | 具有配给接口的药剂递送装置和控制该装置的方法 |
CA2835512A1 (en) | 2011-05-25 | 2012-11-29 | Sanofi-Aventis Deutschland Gmbh | Medicament delivery device with cap |
EP2537546A1 (en) | 2011-06-21 | 2012-12-26 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with dose control mechanism |
CN103648552B (zh) | 2011-07-15 | 2016-08-31 | 赛诺菲-安万特德国有限公司 | 带机电式驱动机构的药物递送装置 |
CN103857427B (zh) | 2011-07-25 | 2018-01-30 | 普雷斯弗雷克斯股份公司 | 流体分配器 |
WO2013029999A1 (en) | 2011-09-02 | 2013-03-07 | F. Hoffmann-La Roche Ag | Dosing unit for an ambulatory infusion device |
US9707335B2 (en) | 2011-09-02 | 2017-07-18 | Unitract Syringe Pty Ltd | Drive mechanism for drug delivery pumps with integrated status indication |
WO2013030000A1 (en) | 2011-09-02 | 2013-03-07 | F. Hoffmann-La Roche Ag | Dosing unit for an ambulatory infusion device |
US8905944B2 (en) | 2011-09-07 | 2014-12-09 | Vlv Associates, Inc. | Protective cover assembly for a needle assembly |
BR112014005272B1 (pt) | 2011-09-09 | 2021-01-19 | Merck Patent Gmbh | autoinjetor recarregável para injeção de adrenalina |
JP6109834B2 (ja) * | 2011-10-07 | 2017-04-05 | ノボ・ノルデイスク・エー/エス | 3軸磁気センサに基づいて要素の位置を決定するシステム |
IL216158A0 (en) * | 2011-11-06 | 2011-12-29 | Medimop Medical Projects Ltd | Electronic autoinjector apparatus and cassettes for use therewith |
JP6424089B2 (ja) | 2011-11-07 | 2018-11-14 | イーライ リリー アンド カンパニー | 人間工学的改善を施した注射器具 |
DE102011119000A1 (de) | 2011-11-21 | 2013-05-23 | Liebherr-Verzahntechnik Gmbh | Verzahnmaschine und Verfahren zur Herstellung oder Bearbeitung von Verzahnungen |
WO2013076026A1 (en) | 2011-11-22 | 2013-05-30 | Sanofi-Aventis Deutschland Gmbh | Pen-type drug injection device with controller and time lock-out mechanism its drive |
US20140108031A1 (en) | 2011-12-29 | 2014-04-17 | Daniel Ferrara | System and method for increasing medication adherence rates |
CN104245022A (zh) | 2012-01-31 | 2014-12-24 | 普雷斯弗雷克斯股份公司 | 使用干燥载体的注射设备 |
WO2013115843A1 (en) | 2012-01-31 | 2013-08-08 | Medimop Medical Projects Ltd. | Time dependent drug delivery apparatus |
EP2628494A1 (en) | 2012-02-17 | 2013-08-21 | Sensile Pat AG | Liquid storage and delivery system |
WO2013127428A1 (en) | 2012-02-27 | 2013-09-06 | F. Hoffmann-La Roche Ag | Spring force assembly for biasing or actuating stoppers of syringes, injection pen cartridges and the like |
US20130226608A1 (en) | 2012-02-28 | 2013-08-29 | Christopher Di Lascia | System for identifying, monitoring, influencing and rewarding healthcare behavior |
MX347426B (es) | 2012-03-02 | 2017-04-26 | Abbvie Inc | Aparato de entrenamiento de inyeccion automatica. |
US10010676B2 (en) | 2012-03-13 | 2018-07-03 | Becton Dickinson France | Method of manufacture for a miniaturized drug delivery device |
US9072827B2 (en) | 2012-03-26 | 2015-07-07 | Medimop Medical Projects Ltd. | Fail safe point protector for needle safety flap |
EP2836261B1 (en) | 2012-04-13 | 2020-01-15 | Becton, Dickinson and Company | Infusion device with safety feature for preventing inadvertent activation |
US9335910B2 (en) | 2012-04-23 | 2016-05-10 | Tandem Diabetes Care, Inc. | System and method for reduction of inadvertent activation of medical device during manipulation |
EP2656865A1 (en) * | 2012-04-24 | 2013-10-30 | Sanofi-Aventis Deutschland GmbH | Syringe carrier with needle shield and data storage device for use in a medical auto-injection device |
US8817258B2 (en) | 2012-05-21 | 2014-08-26 | Common Sensing Inc. | Dose measurement system and method |
CN112138240B (zh) * | 2012-05-24 | 2023-04-07 | 德卡产品有限公司 | 用于输注流体的装置 |
US9715327B2 (en) | 2012-06-07 | 2017-07-25 | Tandem Diabetes Care, Inc. | Preventing inadvertent changes in ambulatory medical devices |
EP2674179A1 (en) | 2012-06-15 | 2013-12-18 | Ares Trading S.A. | Injection device |
US8700133B2 (en) * | 2012-06-18 | 2014-04-15 | Smart Iv Llc | Apparatus and method for monitoring catheter insertion |
AU2013286669B2 (en) * | 2012-07-05 | 2018-02-01 | Unl Holdings Llc | Automatic injectors for injectable cartridges and drive control mechanisms therefor |
EP2682141A1 (en) | 2012-07-06 | 2014-01-08 | Sanofi-Aventis Deutschland GmbH | Injection system |
US20140012511A1 (en) | 2012-07-09 | 2014-01-09 | Dexcom, Inc. | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
US10292641B2 (en) | 2012-07-10 | 2019-05-21 | Becton Dickinson France S.A.S. | Integrated injection system and communication device |
US8454557B1 (en) | 2012-07-19 | 2013-06-04 | Asante Solutions, Inc. | Infusion pump system and method |
AU2013297012B2 (en) | 2012-07-31 | 2017-03-30 | Trividia Healthcare Systems, Llc | Device and method for dispensing fluid from an infusion pump |
EP2698180A1 (en) | 2012-08-15 | 2014-02-19 | Sanofi-Aventis Deutschland GmbH | Autoinjector |
US9867929B2 (en) | 2012-08-15 | 2018-01-16 | Becton, Dickinson And Company | Pump engine with metering system for dispensing liquid medication |
CA2881305C (en) * | 2012-08-29 | 2021-05-04 | Unitract Syringe Pty Ltd | Variable rate controlled delivery drive mechanisms for drug delivery pumps |
WO2014037331A1 (en) | 2012-09-06 | 2014-03-13 | Sanofi-Aventis Deutschland Gmbh | Pen-type drug injection device and electronic add-on monitoring module for monitoring and logging dose setting and administration |
US20140088554A1 (en) * | 2012-09-24 | 2014-03-27 | Po-Ying Li | Drug-delivery pump with intelligent control |
US9782538B2 (en) | 2012-09-27 | 2017-10-10 | Becton, Dickinson And Company | Angled inserter for drug infusion |
EP2716317A1 (en) | 2012-10-04 | 2014-04-09 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with trigger button |
US9789250B2 (en) | 2012-10-05 | 2017-10-17 | Becton, Dickinson And Company | Infusion set with safety device |
JP2014079325A (ja) * | 2012-10-15 | 2014-05-08 | Seiko Epson Corp | 流体注入装置 |
EP2722065A1 (en) | 2012-10-18 | 2014-04-23 | Sanofi-Aventis Deutschland GmbH | Auto-injector |
JP6205701B2 (ja) | 2012-10-22 | 2017-10-04 | セイコーエプソン株式会社 | 流体注入装置 |
GB201218913D0 (en) | 2012-10-22 | 2012-12-05 | Ucb Pharma Sa | Auto-injector and drive unit therefor |
US20150290396A1 (en) | 2012-10-23 | 2015-10-15 | Insuline Medical Ltd. | Drug dispensing-tracking device, system and method |
JP2014087449A (ja) | 2012-10-30 | 2014-05-15 | Seiko Epson Corp | 液体輸送装置及びカテーテルの抜け判定方法 |
US20160067347A1 (en) | 2012-12-20 | 2016-03-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
GB2526948A (en) | 2012-12-27 | 2015-12-09 | Kaleo Inc | Systems for locating and interacting with medicament delivery devices |
DE202013000411U1 (de) | 2013-01-16 | 2013-01-24 | H & B Electronic Gmbh & Co. Kg | Dauerinfusionsvorrichtung |
CN109568719A (zh) | 2013-01-25 | 2019-04-05 | 尤尼特拉克特注射器控股有限公司 | 用于输药泵的液体限制机构 |
WO2014116274A1 (en) | 2013-01-25 | 2014-07-31 | Unitract Syringe Pty Ltd | Integrated sliding seal fluid pathway connection and drug containers for drug delivery pumps |
PL2764881T3 (pl) | 2013-02-06 | 2018-02-28 | Medirio Sa | System leczenia medycznego |
US9446186B2 (en) | 2013-03-01 | 2016-09-20 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
US20140276423A1 (en) | 2013-03-14 | 2014-09-18 | Tandem Diabetes Care, Inc. | Infusion system and methods |
US20140274874A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
CN111499733A (zh) | 2013-03-14 | 2020-08-07 | 美国安进公司 | 三型金属蛋白酶(timp-3)组织抑制剂的变体、组合物和方法 |
EP2967506B1 (en) | 2013-03-15 | 2020-04-29 | Becton, Dickinson and Company | Smart adapter for infusion devices |
US10229607B2 (en) | 2013-04-30 | 2019-03-12 | Elwha Llc | Systems and methods for competency training and use authorization for dispensing an agent |
US9889252B2 (en) | 2013-06-14 | 2018-02-13 | Medtronic, Inc. | Infusion device assembly |
US20150005703A1 (en) | 2013-06-28 | 2015-01-01 | Animas Corporation | Drug infusion device with safety interlock |
DK2865325T3 (en) | 2013-10-23 | 2018-02-19 | Hoffmann La Roche | STANDING ON THE SKIN OF INFUSION PUMP OR CONTINUOUS BLOOD SUGAR MONITOR WITH OPTICAL INDICATION ORGANIZATION |
US10130755B2 (en) | 2013-12-31 | 2018-11-20 | Abbvie Inc. | Devices and methods for delivering a beneficial agent to a user |
EP3177345B1 (en) | 2014-03-14 | 2021-11-10 | SHL Medical AG | A monitoring device |
US10195342B2 (en) | 2014-04-24 | 2019-02-05 | Becton, Dickinson And Company | Cannula deployment mechanism |
JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
-
2015
- 2015-06-03 JP JP2016570991A patent/JP6817074B2/ja active Active
- 2015-06-03 WO PCT/US2015/033946 patent/WO2015187805A2/en active Application Filing
- 2015-06-03 KR KR1020167032417A patent/KR102506614B1/ko active IP Right Grant
- 2015-06-03 US US15/315,817 patent/US10695492B2/en active Active
- 2015-06-03 CA CA2949846A patent/CA2949846C/en active Active
- 2015-06-03 CA CA2948005A patent/CA2948005C/en active Active
- 2015-06-03 EP EP15728736.8A patent/EP3151882B1/en active Active
- 2015-06-03 KR KR1020167032416A patent/KR20170016335A/ko active Application Filing
- 2015-06-03 KR KR1020167032414A patent/KR102506249B1/ko active IP Right Grant
- 2015-06-03 IL IL281354A patent/IL281354B1/en unknown
- 2015-06-03 AU AU2015271767A patent/AU2015271767B2/en active Active
- 2015-06-03 MX MX2016015853A patent/MX2016015853A/es unknown
- 2015-06-03 CA CA2948003A patent/CA2948003C/en active Active
- 2015-06-03 WO PCT/US2015/033925 patent/WO2015187793A1/en active Application Filing
- 2015-06-03 CN CN201580029455.9A patent/CN106470716B/zh active Active
- 2015-06-03 WO PCT/US2015/033935 patent/WO2015187799A1/en active Application Filing
- 2015-06-03 WO PCT/US2015/033939 patent/WO2015187802A1/en active Application Filing
- 2015-06-03 US US15/315,922 patent/US20170124285A1/en active Pending
- 2015-06-03 AU AU2015271769A patent/AU2015271769A1/en not_active Abandoned
- 2015-06-03 US US15/315,954 patent/US20170103186A1/en not_active Abandoned
- 2015-06-03 SG SG11201609970VA patent/SG11201609970VA/en unknown
- 2015-06-03 KR KR1020227035873A patent/KR20220143782A/ko not_active Application Discontinuation
- 2015-06-03 EP EP15730345.4A patent/EP3152694B1/en active Active
- 2015-06-03 EP EP15728737.6A patent/EP3151883A1/en not_active Ceased
- 2015-06-03 MX MX2016015926A patent/MX2016015926A/es unknown
- 2015-06-03 CN CN202010550731.9A patent/CN111840696B/zh active Active
- 2015-06-03 JP JP2016570990A patent/JP6808494B2/ja active Active
- 2015-06-03 CN CN201580028862.8A patent/CN106470717B/zh active Active
- 2015-06-03 KR KR1020167032415A patent/KR102416904B1/ko active IP Right Grant
- 2015-06-03 AU AU2015271676A patent/AU2015271676A1/en not_active Abandoned
- 2015-06-03 CN CN202111156962.2A patent/CN113990437A/zh active Pending
- 2015-06-03 US US15/315,896 patent/US20170098058A1/en not_active Abandoned
- 2015-06-03 SG SG10201806528QA patent/SG10201806528QA/en unknown
- 2015-06-03 CA CA2948525A patent/CA2948525A1/en active Pending
- 2015-06-03 MX MX2016015851A patent/MX2016015851A/es unknown
- 2015-06-03 JP JP2016571023A patent/JP6822843B2/ja active Active
- 2015-06-03 US US15/315,829 patent/US10646652B2/en active Active
- 2015-06-03 SG SG11201609966SA patent/SG11201609966SA/en unknown
- 2015-06-03 KR KR1020237007289A patent/KR20230037063A/ko not_active Application Discontinuation
- 2015-06-03 EP EP22158912.0A patent/EP4036924A1/en active Pending
- 2015-06-03 SG SG11201609972RA patent/SG11201609972RA/en unknown
- 2015-06-03 MX MX2016015854A patent/MX2016015854A/es unknown
- 2015-06-03 CN CN201580029453.XA patent/CN106488782B/zh active Active
- 2015-06-03 AU AU2015271763A patent/AU2015271763B2/en active Active
- 2015-06-03 CN CN202010825780.9A patent/CN112237662B/zh active Active
- 2015-06-03 SG SG11201609963PA patent/SG11201609963PA/en unknown
- 2015-06-03 JP JP2016571049A patent/JP6742248B2/ja active Active
- 2015-06-03 IL IL297356A patent/IL297356A/en unknown
- 2015-06-03 WO PCT/US2015/033933 patent/WO2015187797A1/en active Application Filing
- 2015-06-03 SG SG10201806563QA patent/SG10201806563QA/en unknown
- 2015-06-03 CN CN201580029198.9A patent/CN106663139A/zh active Pending
- 2015-06-03 EP EP15729033.9A patent/EP3151884A1/en active Pending
-
2016
- 2016-11-03 IL IL248731A patent/IL248731B/en active IP Right Grant
- 2016-11-03 IL IL248730A patent/IL248730B/en unknown
- 2016-11-06 IL IL248756A patent/IL248756B/en active IP Right Grant
- 2016-11-06 IL IL248757A patent/IL248757B2/en unknown
- 2016-12-01 MX MX2021012555A patent/MX2021012555A/es unknown
- 2016-12-01 MX MX2023003211A patent/MX2023003211A/es unknown
- 2016-12-01 MX MX2023005376A patent/MX2023005376A/es unknown
- 2016-12-02 MX MX2023000722A patent/MX2023000722A/es unknown
-
2020
- 2020-03-04 AU AU2020201600A patent/AU2020201600C1/en active Active
- 2020-03-24 AU AU2020202096A patent/AU2020202096B2/en active Active
- 2020-04-08 US US16/843,622 patent/US11213624B2/en active Active
- 2020-05-13 US US15/931,364 patent/US11738146B2/en active Active
- 2020-06-26 AU AU2020204260A patent/AU2020204260A1/en not_active Abandoned
- 2020-10-22 AU AU2020257127A patent/AU2020257127A1/en not_active Abandoned
- 2020-10-26 JP JP2020178668A patent/JP2021035515A/ja active Pending
- 2020-12-08 JP JP2020203182A patent/JP7100106B2/ja active Active
- 2020-12-23 JP JP2020213220A patent/JP7126540B2/ja active Active
-
2021
- 2021-03-09 IL IL281369A patent/IL281369B/en unknown
- 2021-11-05 AU AU2021261964A patent/AU2021261964B2/en active Active
- 2021-11-23 US US17/534,173 patent/US20220257862A1/en active Pending
-
2022
- 2022-01-05 AU AU2022200026A patent/AU2022200026B2/en active Active
- 2022-06-29 JP JP2022104384A patent/JP2022137121A/ja active Pending
- 2022-08-15 JP JP2022129187A patent/JP2022172150A/ja active Pending
- 2022-09-08 US US17/940,422 patent/US20230098606A1/en active Pending
- 2022-10-19 AU AU2022256116A patent/AU2022256116B2/en active Active
-
2023
- 2023-02-17 US US18/111,064 patent/US20230201461A1/en active Pending
- 2023-06-30 AU AU2023204188A patent/AU2023204188A1/en not_active Abandoned
- 2023-07-06 US US18/218,782 patent/US20230355877A1/en active Pending
- 2023-11-22 AU AU2023270272A patent/AU2023270272A1/en active Pending
- 2023-12-26 JP JP2023218940A patent/JP2024050546A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7126540B2 (ja) | 制御可能な薬物送達システム及び使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220901 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220901 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230815 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240116 |